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Abstract 
 
Metal-based drugs such as cisplatin, carboplatin and oxaliplatin are clinically 
applied in approximately 50% of all cancer treatments. However, these 
platinum(II)-complexes have shown various severe side effects. Therefore 
extensive research for novel non-platinum-based compounds acting as 
chemotherapeutics has been done over the last decades. In clinical studies 
ruthenium(III)-based drugs like KP1019 and NAMI-A exhibited very promising 
activity and it is supposed that the active species of these complexes is the 
analogous ruthenium(II) complex, formed under hypoxic conditions inside the 
tumor cell (“Activation by Reduction” hypothesis). The oxidation state +II of the 
ruthenium metal core can be stabilized by coordination of an arene moiety 
yielding a so called "piano-stool" configuration. A new strategy to improve the 
cytotoxicity is based on the binding of biological active chelating ligands to the 
metal center.  
4-Pyrones (maltol, kojic acid, etc.) are known to possess a high affinity towards 
metal ions and a favorable toxicity profile. Related structures of this ligand 
system are 2- and 4-pyridones. It has been shown by Kay Severin and coworkers 
that ruthenium(II)-arene-complexes bearing 2,3-dihydroxypyridones as chelating 
ligands are able to form metallomacrocycles which could potentially protect the 
complex from cleavage of the bidentate ligand. During this master thesis a set of 
dinuclear organometallic systems based on 2,3-hydroxypyridone-derived ligands 
and ruthenium(II), osmium(II) and rhodium(III)-arene complexes were 
synthesized and characterized by NMR spectroscopy and in some cases by X-
ray diffraction analysis. The stability and reactivity towards biomolecules was 
investigated. Additionally, the potential of these macrocyclic compounds as 
ionophores in aqueous solution in the presence of Li+, Na+ and K+ ions was 
studied. 
  
Zusammenfassung 
 
Heutzutage werden in einem von zwei Fällen platinbasierende Medikamente wie 
Cisplatin, Carboplatin und Oxaliplatin als Chemotherapeutika in Kliniken 
eingesetzt. Aufgrund der großen Anzahl von Nebenwirkungen dieser Platin(II) 
Verbindungen wurde in den letzten Jahrzehnten verstärkt nach neuen nicht-
platinhältigen Verbindungen geforscht, die in der Krebstherapie eingesetzt 
werden können. Hierzu zeigen Ruthenium(III) Komplexe wie KP1019 und NAMI-
A vielversprechende Ergebnisse in klinischen Studien. Als aktive Spezies werden 
deren Ruthenium(II) Analoga angenommen, welche im hypoxischen Milieu des 
Tumors entstehen ("Activation by Reduction" Hypothese). Durch die Koordination 
eines Arenliganden kann die Oxidationsstufe +II stabilisiert werden. Dies führt zu 
einer "piano-stool" Konfiguration des Komplexes. Um deren Zytotoxizität weiter 
zu steigern, können biologisch aktive Moleküle als Chelatliganden an das 
Metallzentrum koordiniert werden. 
4-Pyrone (Maltol, Kojisäure, usw.) sind bekannt für ihre hohe Affinität zu 
Metallionen und weisen außerdem ein sehr günstiges Toxizitätsprofil auf. 
Verwandte Strukturen dieses Ligandensystems stellen 2- und 4 Pyridone dar. Es 
wurde von Kay Severin und Mitarbeitern gezeigt, dass Ruthenium(II)-Aren 
Komplexe mit 2,3-Dihydroxypyridin-derivaten als Liganden Makrozyklen bilden 
können, welche dadurch vor einer möglichen Abspaltung des zweizähnigen 
Chelats geschützt ist. Im Rahmen dieser Masterarbeit wurden eine Reihe von 
zweikernigen organometallischen Systemen basierend auf 3-Hydroxy-2-pyridon-
derivatiesierten Liganden koordiniert an Ruthenium(II), Osmium(II) und 
Rhodium(III) Zentren synthetisiert und mittels NMR Spektroskopie und 
Röntgendiffraktometrie charakterisiert. Die Stabilität in wässriger Lösung und 
deren Interaktion mit Biomolekülen wurde untersucht, sowie deren möglichen 
ionophoren Eigenschaften gegenüber Lithium, Natrium und Kaliumionen.  
Table of Contents 
 
Abbreviations ___________________________________________________15 
1.  Introduction _________________________________________________17 
1.1.  Cancer _____________________________________________________ 17 
1.2.  Carcinogenesis _______________________________________________ 18 
1.3.  Cancer Therapy ______________________________________________ 20 
1.4.  Metal based Drugs ____________________________________________ 21 
1.4.1. Ruthenium based Drugs _____________________________________________ 23 
1.4.2. Osmium and Rhodium based Drugs ____________________________________ 28 
1.5.  3-Hydroxypyridones ___________________________________________ 30 
1.5.1. Metal Cages ______________________________________________________ 32 
2.  Results and Discussion _______________________________________34 
2.1. Synthesis and Characterization of Metal Complexes bearing 3-Hydoxy- __ 
 2-pyridone Ligands ___________________________________________ 34 
2.1.1. Synthesis ________________________________________________________ 34 
2.1.2. Characterization by NMR Spectroscopy _________________________________ 37 
2.1.3. Determination of the Molecular Structure ________________________________ 39 
2.2. Investigations ________________________________________________ 46 
2.2.1. Water Stability and pH Dependency ____________________________________ 46 
2.2.2. Behavior in Alkali Salt Solutions _______________________________________ 49 
2.2.3. GMP-Experiments __________________________________________________ 50 
2.2.4. Intercalation Experiments ____________________________________________ 50 
3. Experimental Part ____________________________________________51 
3.1. Equipment, Materials and Methods ______________________________ 51 
3.1.1. Chemicals ________________________________________________________ 51 
3.1.2. Equipment ________________________________________________________ 51 
3.1.3. Procedures to determine Sensitivity to Alkaline Metal Ions __________________ 52 
3.2. General Procedures ___________________________________________ 52 
  
3.2.1. General Procedure for the Ester Hydrolysis ______________________________ 52 
3.2.2. General Procedure for Pyridone-based Metal Complexes ___________________ 52 
3.3. Synthesis of Precursor Metal Complexes _________________________ 53 
3.3.1. Synthesis of Bis[dichlorido(η6-p-cymene)ruthenium(II)] - p1 _________________ 53 
3.3.2. Synthesis of Bis[dichlorido(η6-p-cymene)osmium(II)] - p2 ___________________ 54 
3.3.3. Synthesis of Bis[dichlorido(η5-pentamethylcyclopentadiene)rhodium(III)] - p3 ___ 55 
3.4. Ligand Synthesis _____________________________________________ 57 
3.4.1. 1-Ethoxycarbonylmethyl-3-hydroxy-2(1H)-pyridone - 1a ____________________ 57 
3.4.2. 1-Carboxylmethyl-3-hydroxy-2(1H)-pyridone - 2a _________________________ 59 
3.4.3. 1-Ethyoxycarbonylmethyl-3-hydroxy-4-morpholinomethyl-2(1H)-pyridone - 1i ___ 61 
3.4.4. 1-Ethyoxycarbonylmethyl-3-hydroxy-4-methyl-2-(1H)-pyridone - 3a ___________ 63 
3.4.5. 1-Carboxylmethyl-3-hydroxy-2(1H)-4-methyl-pyridone - 4a __________________ 65 
3.4.6. 1-Ethoxycarbonylethyl-3-hydroxy-2(1H)-pyridone - 5a ______________________ 67 
3.4.7. 1-Carboxylethyl-3-hydroxy-2(1H)-pyridone - 6a ___________________________ 69 
3.4.8. 1-Ethyoxycarbonylethyl-3-hydroxy-4-morpholinomethyl-2(1H)-pyridone - 5i _____ 71 
3.4.9. 1-Ethyoxycarbonylethyl-3-hydroxy-4-methyl-2-(1H)-pyridone - 7a _____________ 73 
3.4.10. 1-Carboxylethyl-3-hydroxy-2(1H)-4-methyl-pyridone - 8a ____________________ 75 
3.5. Synthesis of Pyridone-based Metal Complexes ____________________ 77 
3.5.1. [Chlorido(η6-p-cymene){N-[(ethylcarbonyl)methyl]-3-oxo-κO-2-(1H)-pyridonato-
 κO}ruthenium(II)] - 1b _______________________________________________ 77 
3.5.2. [Chlorido(η6-p-cymene){N-[(ethylcarbonyl)methyl]-3-oxo-κO-2-(1H)-pyridonato-
 κO}osmium(II)] - 1c _________________________________________________ 79 
3.5.3. [Chlorido(η5-pentamethylcyclopentadiene){N-[(ehtylcarbonyl)-methyl)]-3-oxo-κO-2-
 (1H)-pyridonato-κO}rhodium(III)] - 1d ___________________________________ 81 
3.5.4. Bis[(η6-p-cymene){N-[(carboxyl-κO)methyl]-3-oxo-κO-2-(1H)-pyridonato-
 κO}ruthenium(II)] - 2b _______________________________________________ 83 
3.5.5. Bis[(η6-p-cymene){N-[(carboxyl-κO)methyl]-3-oxo-κO-2-(1H)-pyridonato-
 κO}osmium(II)] - 2c _________________________________________________ 85 
3.5.6. Bis[(η5-pentamethylcyclopentadiene){N-[(ethoxycarbonyl)-methyl]-3-oxo-κO-2-(1H)-
 pyridonato-κO}rhodium(III)] - 2d _______________________________________ 87 
3.5.7. [Chlorido(η6-p-cymene){N-[(ethylcarbonylmethyl]-3-oxo-κO-4-methyl-2-(1H)-
 pyridonato-κO}ruthenium(II)] - 3b ______________________________________ 89 
3.5.8. [Chlorido(η6-p-cymene){N-[(ethylcarbonylmethyl]-3-oxo-κO-4-methyl-2-(1H)-
 pyridonato-κO}osmium(II)] - 3c ________________________________________ 91 
3.5.9. [Chlorido(η5-pentamethylcyclopentadiene){N-[(ehtylcarbonyl)-methyl)]-3-oxo-κO- __ 
 4-methyl-2-(1H)-pyridonato-κO}rhodium(III)] - 3d __________________________ 93 
3.5.10. Bis[(η6-p-cymene){N-[(carboxyl-κO)ethyl]-3-oxo-κO-4-methyl-2-(1H)-pyridonato-
 κO}ruthenium(II)]- 4b _____________________________________________ 95 
3.5.11. Bis[(η6-p-cymene){N-[(carboxyl-κO)ethyl]-3-oxo-κO-4-methyl-2-(1H)-pyridonato-
 κO}ruthenium(II)]- 4c _____________________________________________ 97 
3.5.12. Bis[(η5-pentamethylcyclopentadiene){N-[(ethoxycarbonyl)-methyl]-3-oxo-κO- ___ 
 4-methyl-2-(1H)-pyridonato-κO}rhodium(III)] - 4d________________________ 99 
3.5.13. [Chlorido(η6-p-cymene){N-[(ethylcarbonyl)ethyl]-3-oxo-κO-2-(1H)-pyridonato-
 κO}ruthenium(II)] - 5b ____________________________________________ 101 
3.5.14. [Chlorido(η5-pentamethylcyclopentadiene){N-[(ehtylcarbonyl)ethyl)]-3-oxo-κO- __ 
 2-(1H)-pyridonato-κO}rhodium(III)] - 5d ______________________________ 103 
3.5.15. Bis[([(η6-p-cymene){N-(Carboxyl-ethyl)-3-oxo-κO-2-(1H)-pyridonato-
 κO}ruthenium(II)] - 6b ____________________________________________ 105 
3.5.16. Bis[([(η5-pentamethylcyclopentadiene){N-[(ethoxycarbonyl)ethyl]-3-oxo-κO-2-
 (1H)-pyridonato-κO}rhodium(III)] - 6d ________________________________ 107 
3.5.17. [Chlorido(η6-p-cymene){N-[(ethylcarbonyl)ethyl]-3-oxo-κO-4-methyl-2-(1H)-
 pyridonato-κO}ruthenium(II)] - 7b ___________________________________ 109 
3.5.18. [Chlorido(η6-p-cymene){N-[(ethylcarbonyl)ethyl]-3-oxo-κO-4-methyl-2-(1H)-
 pyridonato-κO}osmium(II)] - 7c _____________________________________ 111 
3.5.19. [Chlorido(η5-pentamethylcyclopentadiene){N-[(ehtylcarbonyl)ethyl)]-3-oxo-κO- __ 
 4-methyl-2-(1H)-pyridonato-κO}rhodium(III)] - 7d_______________________ 113 
3.5.20. Bis[([(η6-p-cymene){N-(Carboxyl-ethyl)-3-oxo-κO-4-methyl-2-(1H)-pyridonato-
 κO}ruthenium(II)] - 8b ____________________________________________ 115 
3.5.21. Bis[([(η5-pentamethylcyclopentadiene){N-[(ethoxycarbonyl)ethyl]-3-oxo-κO-4-
 methyl-2-(1H)-pyridonato-κO}rhodium(III)] - 8d ________________________ 117 
4. Conclusion and Outlook ____________________________________ 119 
  
|15 
 
Abbreviations 
 
°C degree Celsius 
2,3-DHP 2,3-dihydroxypyridine 
brs broad singlet (NMR) 
CD3OD deuterated methanol 
CDCl3 deuterated chloroform 
cp* pentamethyl-cyclopentadiene 
cym p-cymene 
d doublet (NMR) 
D2O deuterated water 
d6-DMSO (deuterated) dimethyl sulfoxide 
e.g. example given 
eq equivalent 
Et2O diethyl ether 
etc. et cetera 
EtOH ethanol 
g gram 
Hz hertz 
IC50 drug concentration that causes 50% inhibition (of cell growth) 
M molar 
m multiplet (NMR) 
MeOH methanol 
mg milligram 
NaOMe sodium methoxide 
NMR nuclear magnetic resonance 
pD pondus deuterii (power of deuterium) 
pH pondus hydrogenii (power of hydrogen) 
pKa negative decadic logarithm of the acid dissociation constant 
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pKa* negative decadic logarithm of the acid dissociation constant for 
deuterium 
ppm parts per million 
q quartet (NMR) 
s singlet (NMR) 
t  triplet (NMR) 
δ chemical shift (NMR) 
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1.  Introduction 
1.1.  Cancer 
In economically developed countries cancer after cardiovascular diseases is the 
second most leading cause of death. In 2010 19.757 people died due to this 
disease in Austria.1 
Cancer is known for a broad range of different tissues, for example lung or breast 
cancer and is classified according to WHO guidelines 2  that show a wide 
spectrum of malignant neoplasm (see figure 1).3 
The most frequent incident for men is prostate cancer and for women breast 
cancer (see figure 1). 
 
Figure 1 - Most common tumor types for men and women (2009)3 
 
 
                                                      
1
 Statistik Austria 
2
 http://apps.who.int/classifications/icd10/browse/2010/en#/II 
3
 http://www.statistik.at/web_de/wcmsprod/groups/b/documents/webobj/020524.gif 
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An early diagnosis of the disease is important for the therapy and therefore for 
survival of the patient. Characteristics of cancer cells include uncontrolled 
growth, invasion of nearby tissue and often formation of metastases. 
1.2.  Carcinogenesis 
Gene mutations can arise spontaneously or can be induced. Spontaneous 
mutations naturally occur in all cells, whereas induced mutations are produced by 
mutagens or mutagenic agents, which are the predominant factor for gene 
mutations. Mutagens can be of chemical, physical (radiation) or biological 
(bacteria, viruses) origin. They are able to act by at least three different 
mechanisms. A nucleobase of the DNA can be replaced, altered (so that it 
specifically mispairs with another base) or damaged (so that it can't interact with 
its counterpart anymore). Most of these mutations have no effect, because of the 
degenerative coding of the DNA, due to the repair mechanisms of the cell or the 
recessive characteristic of the mutation. The repair mechanisms of cells take 
some time and cancer cell proliferation is usually faster than cell repair. This 
characteristic is important for cancer therapy.4 
 
The complex multi-step process in which a normal healthy cell transforms into a 
malignant tumor cell is called carcinogenesis. The different progress stages are 
called initiation, promotion, conversion and finally the progression step (see 
figure 2). 
In the initiation step a gene is modified spontaneously or by a mutagen. If cell 
division happens before the repair mechanism of the DNA and/or the 
programmed cell death occurs, the mutation is given to the next cell generation. 
During the promotion step cell proliferation is either accelerated or the DNA is 
indirectly damaged by endogenous and exogenous substances (e.g. hormones, 
alcohol, tobacco smoke, etc.). These substances have to be present for some 
                                                      
4
 Anthony J.F. Griffiths et al, An Introduction to Genetic Analysis, W.H. Freeman an Company, 
New York, 7th Edithion, 2000. 
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time (from weeks to years) to show an effect on the initiated cells. The so grown 
preneoplastic cell population is called a benign tumor, which has not invaded 
other tissue. Until this point, the whole process is reversible and apoptosis can 
occur. 
Further mutations lead to the formation of a malignant tumor (conversion). It is 
possible that the second mutation can follow right after the initiation step. During 
the last step, the malignant tumor cells proliferate uncontrolled and start to 
invade other organs or tissue and spreading metastasis.5,6 
 
 
Figure 2 - Steps during carcinogenesis 
                                                      
5
 C. M. Haskell, Cancer Treatment, Saunders, Philadelphia 2000. 
6
 P. A. Oliveira, A. Colaço, R.l Chaves, H. Guedes-Pinto, L.F. De-La-Cruz, P. Carlos Lopes, An 
Acad Bras Cienc, 2007, 79 (4), 593-616. 
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1.3.  Cancer Therapy 
A single cure for cancer is not possible due to the fact that cancer describes a 
variety of different diseases. The treatment is different for each patient and tumor 
type and depends on his/her health conditions as well as on the class and the 
progression of the tumor. The three main therapies are surgery, radiation therapy 
and chemotherapy. A combination of the three types is often practiced in modern 
cancer therapy. 
 
Surgery is used for solid tumors, which are at an early stage or after chemo- or 
radiation therapy, when the size of tumor tissue has been decreased. Generally 
an additional cycle of medication or radiation treatment follows. 
 
Radiation therapy uses ionizing radiation (x-ray or gamma ray, radioactive 
radiation) to harm and destroy the cancer cells. However, due to the induced 
damage to healthy cells, severe side effects can occur, which depend on the 
irradiated tissue (e.g. flush, mucositis, diarrhea, impairment of lung function, 
etc.).7 
 
Chemotherapy: uses synthetic or natural chemical substances with low 
molecular weight for cancer treatment. Such compounds can interfere with the 
DNA replication of malignant tumor cells, inhibit proteins involved in the cell cycle 
or damage the cell in another way. As with radiation therapy, severe side effects 
occur during the treatment (e.g. hemogram changes, hair loss, nausea, 
mucositis, etc.)  
 
                                                      
7
 http://www.krebshilfe-wien.at/Strahlentherapie.106.0.html?&L=myqrgfkmkdnnpk#c358 
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Most of the applied chemotherapeutics can be divided in following classes:  
 
 Alkylating and intercalating agents: alter DNA, can induce strain breaks or 
cross-link DNA, inhibit RNA and proteins to hinder transcription and 
translation of the DNA. Examples are triazines (e.g. dacarbazine), nitrogen 
mustardes (e.g. cyclophospamide), alkyl sulfonates (e.g. busulfan) and 
platinum(II) complexes (e.g. Cisplatin, Carboplatin) 
 Anti-metabolites: mimic nucleobases and can be implemented to the DNA 
or RNA of the cancer cell to stop transcription and translation. Examples 
are folic acid analogues (e.g. methotrexate), pyrimidine analogues (e.g. 5'-
flourouracil, floxuridine), purine analogues (e.g. tioguanine) and 
topoisomerase inhibitors (e.g. topotecan, etoposide). 
 Mitosis Inhibitors: are plant alkaloids and terpenoids that prevent cell 
division by interfering with the microtubule function. Examples are vinca 
alkolids and taxanes. 
 
Additional classes of chemotherapeutics include hormone inhibitors, cytotoxic 
antibiotics (e.g. anthracycline, mitoxantrone, bleomycine), antibodies, signal 
transduction inhibitors and enzyme inhibitors.5 
 
1.4.  Metal based Drugs 
Since ancient times metals play an important role for mankind, not only in making 
tools and weapons, but also for medicine. Metals were used as salts or in 
elementary state for medication. For example arsenic salts were applied in 
ancient Greece for treating asthma.8 Mercury, was also used for treating gastro-
intestinal diseases and is still used as amalgam for dental filing in modern times. 
                                                      
8
 D. Doyle, British Journal of Haematology 2009, 145, 309-317. 
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Nowadays metal based drugs are established and widely used (e.g. cisplatin, 
auranofin, lithium). 
 
During an investigation in the 1960's of the effects of electric fields on bacterial 
growth Barnett Rosenberg discovered that in the presence of platinum (from the 
electrodes), ammonium chloride and sunlight E. coli bacteria didn't proliferate. 
Instead they formed long filaments (up to 300 times bigger). The under these 
conditions generated cis-diamminedichloridoplatinum(II) (cisplatin), was 
responsible for the arrest of cell division.9 This feature of cisplatin was of high 
importance for new metal based anti-cancer drugs. The huge success of cisplatin 
started the research for other platinum and non-platinum metal based drugs.  
Nowadays platinum compounds are widely used as chemotherapeutics and 
cisplatin, carboplatin and oxaliplatin (see figure 3) are in worldwide clinical use.  
 
 
Figure 3 - Platinum-based anticancer drugs in clinical use 
 
Cisplatin coordinates to the DNA and hinders the DNA replication by bending the 
DNA strain. The mode of action is as follows: cisplatin is transported into the cell, 
is hydrolyzed in the cytoplasma and transported to the cells core. There the 
                                                      
9
 B. Rosenberg, L. Van Camp, T. Krigas, Nature 1965, 205, 698-699. 
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DNA-cisplatin-adduct can be formed, but it can also bind to RNA and sulfhydryl 
groups of proteins, which is supposed to inactive the compound.10 Oxaliplatin 
and carboplatin shows a similar mode of action. Oxaliplatin is also effective 
against certain types of cancer, for where cisplatin shows less to no activity (e.g. 
colon cancer). 
 
Platinum compounds are used for about 50% of cancer treatments nowadays, 
but not every tumor type is sensitive to them. Due to the numerous side effects 
(e.g. nephrotoxicity, neurotoxicity for cisplatin) and the intrinsic and acquired 
resistances of some tumors, researchers focus on the development of novel 
(non-)platinum based chemotherapeutics. 
 
1.4.1. Ruthenium based Drugs 
 
During the last decades a broad range of metal complexes have been developed 
and investigated for their anticancer potential and ruthenium complexes have 
shown very promising results in vitro and in vivo.11 These compounds possess a 
similar ligand exchange rate compared to platinum(II)-compounds, are stable at 
different oxidation states (II, III, IV) under physiological conditions and features 
an octahedral ligand geometry. Because of the similarity of ruthenium to iron, 
they can also bind to transport proteins (albumin, transferrin), leading to an 
improved selectivity and lower toxicity, indicating a different mode of action 
compared to platinum-based drugs.  
Two pathophysiological characteristics of solid tumors are an overexpression of 
iron transporting protein receptors (transferrin-receptors) 12  and a surrounding 
                                                      
10
 Robert R. Crichton, Biological Inorganic Chemistry An Introduction, Elsevier B. V., Netherlands, 
1st Edition, 2008. 
11
 C.G. Hartinger, M.A. Jakupec, S.Zorbas-Seifried, M. Groessl, A. Egger, W. Berger, H. Zorbas, 
P.J. Dyson, B.K. Keppler, Chemistry and Biodiversity 2008, 5, 2140-2155. 
12
 F. Kratz, B. K. Keppler, M. Hartmann, L. Messori, M. R. Berger, Metal-based Drugs 1996, 3(1), 
15-23. 
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reductive milieu, based on the insufficient nutrient and blood supply (hypoxic 
milieu).13  The ruthenium(III)-complex is supposed to be reduced to the more 
reactive ruthenium(II) species under these conditions. This step is called 
“activiation by reduction” and was first postulated by Clarke in the 1980’s.14  
The most promising compounds so far are KP1019 (respective the sodium salt 
KP1339) and NAMI-A (see figure 4), which are currently investigated in clinical 
trials. 
 
 
Figure 4 - Ruthenium(III) compounds in clinical phase I 
 
After intravenous formulation of KP1019 a fast binding to the blood proteins 
albumin and transferrin can be observed and the formed adducts are 
accumulated within the tumor cell, where after reduction the active ruthenium(II)-
analog can interact with biological targets. Experiments in freshly explanted 
human tumor samples, including specimens with resistance to standard 
antineoplastic agents showed activity in a broader spectrum of tumors.  
                                                      
13
 S. Kapitza, M. Pongratz, M. Jakupec, W. Berger, L. Lackinger, B.K. Keppler, B. Marian, Journal 
of Cancer Research and Clinical Oncology 2004, 131(2), 101-110. 
14
 M. J. Clarke, Met. Ions. Biot. Syst. 1980, 11, 231. 
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NAMI-A on the other hand showed only minor activity against primary tumors but 
possess some antimetastatic potential. Both compounds already passed clinical 
phase I and KP1339 will enter clinical phase II soon. Investigations on the 
potential biological targets are in progress.15 
 
As a consequence of the "activation by reduction" hypothesis by Clarke, 
ruthenium (II) complexes were studied for their cytotoxicity. The oxidation state 
+II can be stabilized by coordination of an arene moiety (e.g. benzene, biphenyl, 
dihydroanthracene, p-cymene, etc.). The three remaining binding sites of the so 
called "piano-stool" configuration (position X, Y, Z, see Figure 5) can contain 
various mono-, di- or tridentate ligands. 
 
 
Figure 5 - Ruthenium(II)-complex geometry - "piano-stool" configuration 
 
The positions X and Y are often occupied by a chelating ligand, e.g. 
ethylenediamine, which can provide additional stability, whereas in position Z 
halido ligand is often coordinated to the metal center, which acts as a leaving 
group. Hydrolysis of the Ru-halido bond appears to be important for activation, 
yielding the highly reactive aqua species, which can interact with the biological 
target, implying a different mode of action as for ruthenium(III)-compounds.16,17,18 
                                                      
15
 M. Galanski, B.K. Keppler, Tumorhemmende Metallverbindungen, Pharm. Unserer Zeit, 2/2006 
(35). 
16
 A. Habtemariam, M. Melchart, R. Fernandez, S. Parsons, I.D.H. Oswald, A. Parkin, F.P.A. 
Fabbiani, J.E. Davidson, A. Dawson, R.E. Aird, D.I. Jodrell, P.J. Sadler, J. Med. Chem. 2006, 49, 
6858–6868. 
17
 W. H. Ang, A. Casini, G. Sava, P.J. Dyson, Journal of Organometallic Chemistry 2011, 696, 
989-998. 
18
 D.J.M. Snelders, A. Casini, F. Edafe, G. van Koten, R.J.M. Klein Gebbink, P. J. Dyson, Journal 
of Organometallic Chemistry 2011, 696, 1108-1116. 
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Sadler and coworkers studied the influence of the arene ligand on biological 
activity of the ruthenium(II) complexes with the general form [Ru(η6-arene)(en)X] 
(en = ethylenediamine, X = Cl, Br, I). It was found that the cellular uptake 
increase with the lipophilicity of the arene ligand.19 p-Cymene is often used as 
arene ligand.  
Alteration of the first reported Ruthenium(II)-arene complex ([RuCl2(DMSO)(η6-
C6H6)] 20  led to the development of the PTA (= 1,3,5-triaza-7-phospha-
adamantane) based family of RAPTA complexes (see figure 6), which exhibits an 
increased aqueous solubility, antimetastatic effects as well as a lower general 
toxicity, comparable to NAMI-A.21 
 
 
Figure 6 - [RuCl2(DMSO)(C6H6)] and RAPTA-C 
 
The tendency today is to develop metal-complexes bearing biologically active 
compounds, which can induce synergetic effects due to the coordination.22 
 
3-Hydroxy-4-pyrones as natural products with a low toxicity profile offer a broad 
range of different derivatisation possibilities. They can be used as chelating 
                                                      
19
 R. E. Aird, J. Cummings, A. A. Ritchie, M. Muir, R. E. Morris, H. Chen, P. J. Sadler, D. I. 
Jodrell, Br. J. Cancer 2002, 86, 1652-1657. 
20
 L.D. Dale, J.H. Tocher, T.M. Dyson, D.I. Edwards, D.A. Tocher, Anti-Cancer Drug Design 1992, 
7(1), 3-14. 
21
 C. Scolaro, A. Bergamo, L. Brescacin, R. Delfino, M. Cocchietto, G. Laurenczy, T.J. Geldbach, 
G. Sava, P.J. Dyson, J. Med. Chem. 2005, 48, 4161-4171. 
22
 M.A. Jakupec, M. Galanski, V.B. Arion, C.G. Hartinger, B.K. Keppler, Dalton Trans. 2008, 183-
194. 
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ligands due to their high affinity to metal ions yielding highly stable complexes. 
Some examples of pyrone-ligands are shown in figure 7.23,24 
 
 
Figure 7 – Examples for common 3-hydroxy-4-pyrones 
 
Pyrone-based Ruthenium(II) complexes were reported in literature during the last 
years.23 As an example, the maltolato-based ruthenium and osmium complexes 
were investigated by Sadler and co-workers for their behavior in aqueous 
solution and their cytotoxicity in A2780 and A2780cis cell lines. It was observed 
that the ligand exchange (Cl to H2O) was too fast to be monitored by NMR 
spectroscopy. After some time, the maltolato-ligand seemed to be cleaved in 
aqueous solution and a stable but inactive dimeric hydroxido complex of the 
general structure [Ru2(cym)2(OH)3]+ was formed (see scheme 1). The IC50-values 
were determined and no significant in vitro cytotoxicity was observed.25 
 
                                                      
23
 W. Kandioller, A. Kurzwernhart, M. Hanif, S.M. Meier, H. Henke, B.K. Keppler, C.G. Hartinger, 
Journal of Organometallic Chemistry, 2011, 696, 999-1010. 
24
 W. Kandioller, C. G. Hartinger, A. A. Nazarov, C. Bartel, M. Skocic, M. A. Jakupec, V. B. Arion, 
B. K. Keppler, Chem. Eur. J. 2009, 15, 12283-12291. 
25
 A.F.A. Peacock, M. Melchart, R.J. Deeth, A. Habtemariam, S. Parsons, P.J. Sadler, Chem. 
Eur. J. 2007, 13, 2601-2613. 
28|   
 
 
 
Scheme 1 – Hydrolysis of maltolato-cymene-ruthenium(II)-complex forming hydroxido dimer 
 
To stabilize the ruthenium(II) pyronato system, various modified complexes were 
reported.24,26,27,28 For all complexes, a quick aquation to the corresponding aqua 
species by exchange of the halido ligand was observed. Derivatisation at position 
two of the pyrone backbone leads to moderate IC50-values, whereas thionation of 
the 4-oxygen led to IC50-values in the low micromolar range. 
 
1.4.2. Osmium and Rhodium based Drugs 
 
Other elements of the platinum-group are also known for their cytotoxic activity, 
but were only minor investigated during the last decades.  
Due to the similarity to ruthenium, osmium can be another candidate for metal-
based drugs. Like ruthenium, osmium complexes are stable at different oxidation 
states (II, III, IV) under physiologic conditions and several cytotoxic osmium(II) 
analogues of ruthenium(II) arene complexes were reported. 29 , 30 , 31  A general 
                                                      
26W. Kandioller, C.G. Hartinger, A.A. Nazarov, M.L. Kuznetsov, R.O. John, C. Bartel, M.A. 
Jakupec, V.B. Arion, B.K. Keppler, Organometallics 2009, 28, 4249-4251. 
27
 M. Hanif, P. Schaaf, W. Kandioller, M. Hejl, M.A. Jakupec, A. Roller, B.K. Keppler, C.G. 
Hartinger, Aust. J. Chem. 2010, 63, 1521-1528. 
28
 J.H. Kasser, W. Kandioller, C.G. Hartinger, A.A. Nazarov, V.B. Arion, P.J. Dyson, B.K. Keppler, 
Journal of Organometallic Chemistry 2010, 695, 875-881. 
29
 A.F.A. Peacock, S. Parsons and P.J. Sadler, J. Am. Chem. Soc. 2007, 129, 3348–3357. 
30
 A.F.A Peacock, A. Habtemariam, R. Fernandez, V. Walland, F.P.A. Fabbiani, S. Parsons, R.E. 
Aird, D.I. Jodrell, P.J. Sadler, J. Am. Chem. Soc. 2006, 128, 1739–1748. 
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distinction between the activity of osmium and ruthenium as central metal is not 
possible, because of the large influence of the ligand system. Besides the 
ruthenium analogues other osmium complexes were reported, e.g. osmium(VI)-
nitrido complexes, which exhibited an in vitro activity in the micromolar range.32 
 
Rhodium in its oxidation states +I, +II and +III was only of little interest in the last 
decades for anti-cancer drug design. Rhodium(I) complexes are generally known 
for their use as catalysts for hydrogenation or hydroformylation (e.g. Willkinson 
catalyst33). However, rhodium was one of the first transition metals that was 
investigated for its cytotoxic activity.9 There are a few compounds reported as 
possible anti-cancer agents in oxidation state +III.34,35,36,37 Some of them are 
similar to ruthenium(II) complexes with piano-stool configuration of general 
composition [Rh(cp*)(X)Cl] (X = chelating ligand).35 Dimeric acetato complexes of 
Rh(II) as well as monomeric Rh(I) and Rh(III) complexes have shown interesting 
anticancer properties.36,38 
 
                                                                                                                                                              
31
 L.K. Filak, G. Mühlgassner, M.A. Jakupec, P. Heffeter, W. Berger, V.B. Arion, B.K. Keppler, J 
Bio.l Inorg. Chem. 2010, 15, 903–918. 
32
 Wen-Xiu Ni, Wai-Lun Man, Shek-Man Yiu, Man Ho, Myra Ting-Wai Cheung, Chi-Chiu Ko, Chi-
Ming Che, Yun-Wah Lam, Tai-Chu Lau, Chem. Sci. 2012, 3, 1582–1588. 
33
 A. F. Holleman, N. Wiberg, Lehrbuch der Anorganischen Chemie, 102. Auflage 2007, Walter 
de Gruyter & Co, Berlin. 
34
 R. Bieda, I. Kitanovic, H. Alborzinia, A. Meyer, I. Ott, S. Wölfl, W.S. Sheldrick, Biometals 2011, 
24, 645-661. 
35
 Y. Geldmacher, R. Rubbiani, P. Wefelmeier, A. Prokop, I. Ott, W.S. Sheldrick, Journal of 
organometallic Chemistry 2011, 696, 1023-1031. 
36
 M. Carneiro, E. Nunes, R. Peixoto, R. Oliveira, L. Lourenço, I. da Silva, A. Simioni, A. Tedesco, 
A. de Souza, Z. Lacava, S. Báo, Journal of Nanobiotechnology 2011, 9, 11. 
37
 S. Wirth, C.J. Rohbogner, M. Cieslak, J. Kazmierczak-Baranska, S. Donevski, B. Nawrot, I.P. 
Lorenz, J Biol Inorg Chem 2010, 15, 429-440. 
38
 N. Katsaros, A. Anagnostopoulou, Crit Rev Oncol Hematol 2002, 42, 297-308. 
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1.5.  3-Hydroxypyridones  
Protected 3-hydroxy-4-pyrones can be converted easily to their corresponding 3-
hydroxypyridones by reaction with ammonia or primary amines (including amino 
acids) in high yields (see scheme 2). As an example for their high affinity to metal 
ions, the relatively non-toxic deferiprone (1,2-dimethyl-3-hydroxy-4(1H)-pyridone) 
can be used for the treatment of iron overload.39 
 
O
O
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N
O
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H2,Pd/C
N
O
OH
R
 
 
Scheme 2 - Conversion of maltol to the corresponding pyridone 
 
Ruthenium and osmium complexes were investigated for their antiproliferative 
potential, whereas di- or trinuclear complexes bearing 3-hydroxy-4-pyridones 
(see figure 8) were synthesized with very promising in vitro antitumor activity 
was.40 
                                                      
39
 A.V. Hoffbrand, A. Cohen, C. Hershko, Blood 2003, 102 17-24. 
40
 M.G. Mendoza-Ferri, C.G. Hartinger, A.A. Nazarov, R.E. Eichinger, M.A. Jakubec, K. Severin, 
B.K. Keppler, Organometallics 2009, 28(21), 6260-6265. 
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Figure 8 - Dinuclear and trinuclear metal complexes (M = Ru, Os; X = Cl, Br, I; n = 6, 8; arene = 
p-cymene, biphenyl) 
 
The isomeric 3-hydroxy-2-pyridones can by synthesized by using the 
commercially available 2,3-DHP. As their close analogues (3-hydroxy-4-
pyridones) they provide many possibilities for derivatisations, e.g. substitution on 
position 4 and 6, thionation or alkylation of the hydroxy group (see figure 9).  
 
Figure 9 - Possible modification sites of the 2-pyridone scaffold; a: mannich reaction, substitution, 
b: thionation, c: N-alkylation, d: alkylation 
 
Both types of pyridones can be easily functionalized at the nitrogen atom or at 
different positions of the pyridone system, which provides an opportunity for fine-
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tuning chemical and biological properties such as lipophilicity, bioavailability, 
chelating ability, etc.23,41,42. 
 
Metal complexes bearing 3-hydroxy-2-pyridone derivates as bidentate ligands 
were investigated for a broad range of biological application, e.g. as potential 
enzyme inhibitors against tuberculosis43 , as metal chelators of Al(III) against 
Alzheimer disease44 and gadolinium complexes as potent MRI-contrast agents 
and also for their cytotoxic potential. 45 ,46,47 These complexes showed a fast 
hydrolyses to the respective aqua species, which is stable for at least five days 
without forming of dimeric hydroxido-ruthenium arene species. However, the 
aqua-complexes react quickly with different amino acids leading to the loss of the 
hydroxypyridone ligand. The osmium compounds seem to be more stable than 
their corresponding ruthenium complexes. The interaction with the DNA-model 
compound 5'-GMP was investigated and coordination of the N7 atom of the 
purine base was observed. The formed adduct was found to be stable for more 
than 24 hours. Unfortunately these compounds showed no in vitro cytotoxic 
activity against the human tumor cell lines CH1 (human ovarian cancer), SW480 
(colon cancer) and A549 (non-small cell lung cancer). 
 
1.5.1. Metal Cages 
 
A special feature of metal complexes bearing 3-hydroxy-2-pyridones is the 
possibility to form macrocyclic systems. Kay Severin and coworkers described a 
                                                      
41
 R.C. Fox, P.D. Taylor, Synthetic Communications, 1998, 28(9), 1563-1574. 
42
 Deng Ruey Hwang, J. S .Driscoll, Journal of Pharmaceutical Sciences 1979, 68(7), 816-819. 
43
 S.L. Williams, C.A.F. de Oliveira, H. Vazquez, J.A. McCammon, Chem. Bio. Drug Des. 2011, 
77, 117-123. 
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 K.H. Thompson, C.A. Barta, C. Orvig, Chem. Soc. Rev. 2006, 35, 545-556. 
45
 E.J. Werner, J. Kozhukh, M. Botta, E.G. Moore, S. Avedano, S. Aime, K.N. Raymond, Inorg. 
Chem. 2009, 48, 277-286. 
46
 V.C. Pierre, M. Botta, S. Aime, K.N. Raymond, J. Am. Chem. Soc. 2006, 128, 5344-5345. 
47
 M. Hanif, H. Henke, S.M. Meier, S. Martic, M. Labib, W. Kandioller, M.A. Jakubec, V.B. Arion, 
H.B. Kraatz, B.K. Keppler, C.G. Hartinger, Inorg. Chem. 2010, 49, 7953-7963. 
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metallomacrocyclic ionophore which is sensitive for alkali metals. The trimeric 
complex can be easily obtained by self-assembly using ruthenium-cymene 
precursor and 2,3-DHP.48 The alkali metal fits in the cavity of this metallocrown 
ether and is stabilzed via the oxygen atoms (see figure 12). Other macrocycles 
were reported by modifying the hydroxypyridone scaffold49,50 or by coordination 
of other ligand systems51 to increase the number of metal cores of the cages, 
which can be selective for metal ions or are able to intercalate organic molecules, 
e.g. coronene or perylene.52 
 
 
Figure 10 - Molecular structure of [η6-p-cymene)(3-oxo-κO-2-(1H)-pyridonato-
κO)ruthenium]3·NaCl without hydrogens and methyl and isopropyl substitutes of the arene ring 
                                                      
48
 H. Piotrowski, K. Polborn, G. Hilt, K. Severin, J. Am. Chem. Soc. 2001, 123, 2699-2700. 
49
 Zacharias Grote, Simone Bonazzi, Rosario Scopelliti, Kay Severin, J. Am. Chem. Soc. 2006, 
128, 10382-10383. 
50
 A. Granzhan, T. Rüs-Johannessen, R. Scopelliti, K. Severin, Angew. Chem. Int. Ed. 2010, 49, 
5515-5518. 
51
 S. Mirtschin, E. Krasniqi, R. Scopelliti, K. Severin, Inorganic Chemistry 2008, 47(14), 6375-
6381. 
52
 B. Therrien, Eur. J. Inorg. Chem 2009, 2445-2453. 
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2.  Results and Discussion 
 
The aim of this master thesis was the synthesis of novel piano-stool configured 
dimeric Ru(II)-(η6-p-cymene), Os(II)-(η6-p-cymene) and Rh(III)-(η5-cp*) 
complexes bearing different N-functionalized 3-hydroxy-2-pyridones as chelating 
ligands. The compounds were characterized by NMR spectroscopy, elemental 
analysis, melting point, water solubility and for some complexes by crystal 
structure analysis and mass spectrometry.  
 
2.1. Synthesis and Characterization of Metal Complexes 
 bearing 3-Hydoxy-2-pyridone Ligands 
2.1.1. Synthesis 
Two different methods were performed to obtain chain length of the spacer with 
one (C1-spacer) or two carbon atoms (C2-spacer) between the nitrogen atom of 
the pyridone ring and the ester group (see scheme 3). Compound 1a (1-
Ethoxycarbonylmethyl-3-hydroxy-2(1H)-pyridone) was synthesized by N-
alkylation of 2,3-DHP according to literature procedure.53  
 
 
Scheme 3 - Synthesis of intermediates of C1 and C2 spacer 
                                                      
53
 M. Streater, P.D. Taylor, R.C. Hider, J. Porters, J. Med. Chem. 1990, 33, 1749-1755. 
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For a chain length of two carbon atoms (C2-spacer) a Michael-addition was 
performed, using 2,3-DHP and ethyl acrylate as reagents and potassium fluoride 
as the catalyst resulting in compound 5a with an excellent yield of 90%. 54 
 
 
 
Scheme 4 - Synthesis of C1 and C2 spacer ligands 
 
Both N-functionalized hydroxypyridones were further modified according to 
literature procedure (scheme 4). 55  Compound 1a (respectively 5a) was 
methylated on position 4 in two steps. In the first step the intermediate was 
modified by Mannich reaction using morpholine and formaldehyde. The isolated 
compound 1i (respectively 5i) was reduced with cyclohexene as a hydrogen 
                                                      
54
 J.H. Clark, Chem. Rev., 1980, 80, 429-452. 
55
 R.C. Fox, P.D. Taylor, Synthetic Communications, 1998, 28(9), 1563-1574. 
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source and in the presence of Pd on charcoal as catalyst yielding compound 3a 
(respectively 7a). Afterwards, hydrolysis of the ester moiety of 1a and 3a 
(respectively 5a and 7a) led to the free acids 2a and 4a (respectively 6a and 8a). 
 
The obtained ligands 1a–8a were converted to their corresponding metal 
complexes under alkaline conditions (as described in section 3.2.2. general 
procedure for pyridone metal complexes) using different dimeric metal precursors 
(bis[(η6-p-cymene)dichlorido ruthenium(II)] - p1, bis[(η6-p-cymene)dichlorido 
osmium(II)] - p2, Bis[dichlorido(η5-pentamethylcyclopentadiene) rhodium(III)] -
p3). By using ligands with carboxylic acid, the formation of dimers of the metal 
complexes was observed (see scheme 5).  
 
 
Scheme 5 - Complexation (A = cym, cp*, M = Ru(II), Os(II), Rh(III), n = 1, 2, R = H, CH3) 
 
A series of different complexes was obtained with variation of the metal center, 
the coordinated arene, mono and dinuclear organometallics and with different 
ligand systems modified at position 4 and various spacer lengths (see table 1). 
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Table 1 - Different ruthenium(II), osmium(II) and rhodium(III) complexes 
Complex ID Ligand ID R A M 
1b 1a H cym Ru 
1c 1a H cym Os 
1d 1a H cp* Rh 
2b 2a H cym Ru 
2c 2a H cym Os 
2d 2a H cp* Rh 
3b 3a CH3 cym Ru 
3c 3a CH3 cym Os 
3d 3a CH3 cp* Rh 
4b 4a CH3 cym Ru 
4c 4a CH3 cym Os 
4d 4a CH3 cp* Rh 
5b 5a H cym Ru 
5d 5a H cp* Rh 
6b 6a H cym Ru 
6d 6a H cp* Rh 
7b 7a CH3 cym Ru 
7c 7a CH3 cym Os 
7d 7a CH3 cp* Rh 
8b 8a CH3 cym Rh 
8d 8a CH3 cp* Rh 
 
2.1.2. Characterization by NMR Spectroscopy 
 
All ligands and complexes were characterized by 1H-NMR spectroscopy. For 
novel compounds 13C-NMR measurements were performed. The aliphatic area of 
the proton spectra of the ligands 1a and 5a were compared (see figure 11). The 
green marked peaks show the CH2-groups of the C1 spacer (bottom spectra, one 
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singlet) and the C2-spacer (top spectra, two triplets). 2D-NMR (HSQC, HMBC, 
1H-COSY and 1H-TOCSY) was performed for ligand 5a for correct peak 
assignment. Through the HMBC experiment two 3J(C,H) couplings to the 
pyridone ring were observed for the peak at 4.13 ppm, while for the peak at 2.75 
ppm no coupling to the aromatic area was monitored. The peak at lower ppm 
shift can therefore be assigned to the CH2 group near the ester moiety and the 
one at higher shift to the CH2-group neighboring the nitrogen atom. 
 
 
Figure 11 - 1H-NMR spectra of the aliphatic area of 5a (top) and 1a (bottom). green marked 
signals represent the spacing CH2-groups 
 
The 1H-NMR spectra of the complexes in CDCl3 show doublets corresponding to 
each proton of the cym ring. The hydrogen atoms of the spacer group are 
diastereotopic, leading to the observation of two doublets, for example for 
compound 2b at 3.89 and 5.12 ppm with a geminal coupling constant 2J(H,H) = 
16 Hz (figure 17, marked green), or four multiplets for C2-spacer complexes like 
7b between 2.7 and 4.4 ppm (figure 18, marked green). In protic solvents, the 
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same protons give a singlet for C1-spacer or two triplets for C2-spacer 
respectively. 45,56 
 
Figure 12 - 1H-NMR spectra of compound 2b in CDCl3. aromatic area; splitting diastereotopic 
protons are marked green 
 
Figure 13 - 1H-NMR spectra of compound 5b in CDCl3. aromatic area; splitting diastereotopic 
protons are marked green. At around 4.15 ppm also signal for ester-CH2-group 
 
2.1.3. Determination of the Molecular Structure 
Single crystals of the complexes 2b, 4c, 4d, 5d and 8b were obtained by the 
slow diffusion method with dichloromethane/Et2O, which were suitable for x-ray 
diffraction analysis. All structures showed the typical "piano-stool" configuration, 
with ruthenium, osmium or rhodium as the central metal, where the η6 π-bound 
cymene ring acts as seat and the pyridone and the chlorido/carboxylato moieties 
                                                      
56
 Z. Grote, M. Lehaire, R. Scopelliti, K. Severin, J. Am. Chem. Soc., 2003, 125, 13638–13639. 
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as the legs. The 3-hydroxy-2-pyridone ligands bind bidentately to the metal 
center via the lactam and alcoholate oxygens, forming a non-planar five-
membered ring. The coordination of the free carboxylate to the metal center 
leads to dimeric structures of the complexes (figure 14, 15 and 16).  
 
 
Figure 14 - Molecular structure of 2b (left) and 4c (right) 
 
Both ruthenium compounds 2b and 8b as well as the rhodium compound 4d 
crystallized in triclinic centrosymmetric space group P-1, the osmium compound 
4c and the rhodium monomer 5d in monoclinic space group C 2/c.  
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The bond lengths and angles between the metal center and the oxygens are very 
similar to each other (listed in table 2). 
 
Table 2 - Bond lengths and angles to the metal center. X = Cl (5d), O3 (2b, 4c, 4d, 8b) 
compound 2b 4c 4d 5d 8b 
r(M1-O1) /Å 2.1029(19) 2.1147(16) 2.1013(28) 2.1270(16) 2.1055(11) 
r(M1-O2) /Å 2.0722(19) 2.0596(17) 2.0735(27) 2.0912(19) 2.0730(13) 
r(M1-X) /Å 2.0790(17) 2.0835(16) 2.1078(32) 2.4214(7) 2.0715(12) 
r(M2-O5) /Å 2.1001(19) 2.1147(16) 2.1203(29) - 2.1055(11) 
r(M2-O6) /Å 2.0760(22) 2.0596(17) 2.0586(29) - 2.0730(13) 
r(M2-O7) /Å 2.0877(20) 2.0835(16) 2.1264(31) - 2.0715(12) 
φ(O1-M1-O2) /° 79.29(8) 76.83(6) 80.42(11) 78.13(5) 78.89(5) 
φ(O2-M1-X) /° 79.34(7) 79.22(7) 81.10(11) 89.12(5) 80.73(5) 
φ(X-M1-O1) /° 79.69(7) 78.75(6) 78.05(12) 84.68(5) 77.95(5) 
φ(O5-M2-O6) /° 79.32(8) 76.83(6) 80.01(11) - 78.89(5) 
φ(O6-M2-O7) /° 78.75(8) 79.22(7) 81.05(11) - 80.73(5) 
φ(O7-M2-O5) /° 80.16(8) 78.75(6) 77.98(11) - 77.95(5) 
 
The four oxygen atoms O1, O3, O5 and O7 of the dimeric metal complexes form 
a twisted tetragon (in case of compound 8b a parallelogram) with different 
distances and angles (listed in table 3), which is confined by the arene ligands 
(C1 spacer) of the complex, leading to the formation of a cavity.  
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Table 3 - Distances and angles of the oxygen tetragon 
compound 2b 4c 4d 8b 
r(O1-O7) /Å 3.289 3.797 3.623 2.627 
r(O3-O5) /Å 3.390 3.797 3.607 2.627 
r(O5-O7) /Å 2.696 2.609 2.650 4.982 
r(O1-O3) /Å 2.676 2.609 2.672 4.982 
φ(O1-O7-O5) /° 94.99 97.00 98.64 108.26 
φ(O3-O5-O7) /° 83.96 82.48 81.65 71.74 
φ(O1-O3-O5) /° 93.03 97.00 98.61 108.26 
φ(O3-O1-O7) /° 86.22 82.48 81.06 71.74 
τ/° 9.12 6.43 1.79 0 
 
Metal ions or (solvent) molecules could be attached by interaction with the 
oxygen atoms. During crystallization of 4c and 4d, a dichloromethane molecule 
was incorporated into this cavity (see figure 15). 
 
 
Figure 15 - Molecular structure of 4d, coordination of dichloromethane to the cavity of 4d (right) 
 
Another possibility for intercalation is by π-stacking between the aromatic rings of 
the pyridone ligands of the C1 spacer complexes with a distance between the 
centroids of 3.949 Å for 2b, 3.798 Å for 2d, and 3.747 Å for 4d. 
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In case of the C2-spacer complexes, the lactam moiety point in opposite 
directions, therefore no intercalation through π-stacking might be possible (see 
figure 16).  
 
 
Figure 16 - Molecular structure of 5d (left) and 8b (right) 
 
The crystal data and details of data collection corresponding to the complexes 
2b, 4c and 4d are listed in table 4, to 5d and 8d in table 5.  
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Table 4 – Crystal data and details of data collection for 2b, 4c and 4d 
compound 2b 4c 4d 
Chemical formula C34H38N2O8Ru2 C37H44Cl2N2O8Os2 C37H50Cl2N2O10Rh2 
M (g mol-1) 809.78 1011.19 959.51 
Temperature (K) 100(2) 100(2) 100(2) 
Crystal size (mm) 0.50 x 0.30 x 0.20 0.10 x 0.10 x 0.04 0.18 x 0.15 x 0.05 
Crystal color, shape orange, block green, block red, block 
Crystal system triclinic monoclinic Triclinic 
Space group P-1 C2/c P-1 
a (Å) 10.3118(5) 16.0277(4) 11.0352(7) 
b (Å) 12.8875(7) 11.1724(4) 12.6088(11) 
c (Å) 13.3610(7) 20.8953(7) 14.7170(13) 
α (°) 85.021(2) 90 110.472(2) 
β (°) 69.737(2) 95.157(2) 91.228(2) 
γ (°) 74.725(2) 90 91.012(2) 
V (Å3) 1606.84(14) 3726.5(2) 1917.3(3) 
Z 2 4 2 
Dc (g cm-3) 1.674 1.954 1.662 
µ (mm-1) 0.997 7.01 1.060 
F (000) 818 2120 980 
θ range (°) 2.17 – 30.15 2.23 – 28.00 2.33 – 25.50 
h range  -14/14 -21/20 -13/13 
k range -18/18 -14/13 -15/15 
l range -18/18 -27/27 -17/17 
no. reflections  52298 45315 31862 
no. parameters 434 233 490 
Rint 0.0293 0.0398 0.0760 
R1a 0.0388 0.0185 0.0435 
wR2b 0.0956 0.0389 0.0999 
GOFc 1.056 1.060 1.037 
Residuals (e- Å-3) 1.466, -1.379 0.919, -0.802 1.050, -0.737 
a: R1 = Σ||F0| – |Fc||/ Σ|F0|  b: wR2 = {Σ[w(F02 – Fc2)2]/wΣ[(F02)2}½ 
c: GOF = {Σ[w(F02 – Fc2)2]/(n – p)½ 
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Table 5 - Crystal data and details of data collection for 5d and 8b 
compound 5d 8b 
Chemical formula C20H27ClNO4Rh C19H23NO4Ru 
M (g mol-1) 483.79 430.45 
Temperature (K) 150(2) 100(2) 
Crystal size (mm) 0.20 x 0.10 x 0.05 0.65 x 0.44 x 0.07 
Crystal color, shape dark red, block dark red, block 
Crystal system Monoclinic triclinic 
Space group C2/c P-1 
a (Å) 36.4313(18) 9.7980(4) 
b (Å) 8.0432(4) 10.1383(4) 
c (Å) 15.3744(7) 10.5159(4) 
α (°) 90 70.104(2) 
β (°) 114.725(4) 75.025(2) 
γ (°) 90 67.311(2) 
V (Å3) 4092.1(3) 896.45(6) 
Z 8 2 
Dc (g cm-3) 1.571 1.595 
µ (mm-1) 0.990 0.897 
F (000) 1984 440 
θ range (°) 2.46 – 30.17 2.26 – 30.15 
h range  -51/51 -13/13 
k range -11/11 -14/14 
l range -21/21 -14/14 
no. reflections  64032 26875 
no. parameters 249 232 
Rint 0.0703 0.0446 
R1a 0.0380 0.0245 
wR2b 0.0869 0.0652 
GOFc 1.022 1.008 
Residuals (e- Å-3) 0.795, -0.858 0.851, -0.786 
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2.2. Investigations 
The water stability, the corresponding pKa-values and their interaction of the 
complexes with the DNA-model compound 5'-GMP were investigated by 1H-NMR 
for selected compounds. 
2.2.1. Water Stability and pH Dependency  
 
Nearly all complexes (except 3b, 3c, 4c, and 5d because of their insufficient 
solubility in water) were dissolved in D2O and 1H-NMR-spectra were recorded 
after 5 minutes, 24 and 48 hours to monitor their stability in aqueous solution. 
Formation of smaller amounts of another species, probably the hydroxido dimer 
was observed for all compounds after 24 hours. This amount didn’t increase 
significantly after additional 24 hours (marked peaks figure 17). In case of the 
rhodium compounds (see figure 18) the formation of a new signal at 2.17 ppm 
was observed.  
 
Figure 17 – 1H-NMR spectra of compound 2b in D2O, p-cym signals 
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Figure 18 – 1H-NMR-spectra of compound 1d in D2O, cp* signals  
 
The ruthenium and rhodium complexes dissolves faster than their osmium 
counterparts, implying a fast hydrolysis to the charged aqua species by 
exchanging of the carboxylate-group of the pyridone ligand or chlorido ligand (in 
case of the mononuclear complexes) by a water molecule which is in accordance 
to the result of the water stability experiment.45 
 
The pH dependent monomerization of the dimeric complexes 2b, 2d, 6b and 6d 
was investigated by measuring proton spectra at different pD values, which were 
adjusted by addition of DNO3 or NaOD to the sample dissolved in D2O. In theory 
at high pD (respectively pH) the dimeric structure should be intact, while at low 
pD values the coordinated carboxylate should be protonated to the 
corresponding free acid leading to the cleavage of the macrocylce and formation 
of a monomeric complex that can be monitored by arising of additional signals. 
But instead formation of new signals in the proton spectra at low pD a shift of the 
signals was observed. This result also indicated that the dimeric complexes were 
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quickly hydrolyzed to their monomeric charged aqua analogues by protonation of 
the carboxylate-group and coordination of a water molecule to the metal core.  
Through these experiments the pKa values of the aqua species of the two 
ruthenium compounds 2b and 6b and the rhodium compounds 2d and 6d were 
determined by plotting the chemical shifts of the aromatic pyridone signals 
against the pD value. 
 
pKa = 0.929 pKa*+0.42     (1) 
 
The inflection point of the sigmoid titration curve represents the pKa* value, which 
were converted to the corresponding pKa values (see table 6) by applying 
equation 1. 57 
 
Table 6 - pKa values 
compound pKa 
2b 9.84 
2d 10.20 
 
No sigmoid curve was observed for compound 6b and 6d in the pD range 
between 2.90 and 10.24. The infliction point may be at higher pD, as it is for 
compounds 2b and 2d. 
 
While adding NaOD or DNO3 to the rhodium compounds new signals were found 
in the 1H-NMR-spectra between 3.30 and 3.80 ppm (see figure 19) that are still 
present when changing the pD back to neutral.  
 
                                                      
57
 A. Krezel, W. Bal, J. Inorg. Biochem. 2004, 98, 161–166. 
|49 
 
 
Figure 19 – 1H-NMR of 2d at different pD-values. Arising of new signals between 3 and 4 ppm 
(marked green) 
 
2.2.2. Behavior in Alkali Salt Solutions 
 
The water stability tests and pKa determination of the dimeric complexes 2b, 2d, 
6b and 6d indicated the dimeric structure was not stable in protic solvents and 
quick hydrolysis of the compound was observed. In organic solvents such as 
chloroform the dimeric structure was intact, proven by crystal structure analyses 
and 1H-NMR spectra in CDCl3. According to the molecular structures of 2b, 4c 
and 8b (see figure 14 and figure 15 in section 2.1.3.) a binding of metal ions on 
the side of the oxygen tetragon might be possible. 
To investigate the sensitivity for alkali metal ions of the compounds 2b, 2d, 6b 
and 6d, two different experimental setups (experimental part, section 3.1.3.), 
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were applied, developed by Kay Severin and coworkers. 58  Based on their 
research more signals in 1H-NMR of the incorporated metal salts are expected 
compared the experiments without salts. However in all experimental setups no 
interaction with lithium, sodium and potassium ions could be observed. 
2.2.3. GMP-Experiments 
 
For DNA-interaction studies, D2O solutions of compounds 1b–d and 2b–d were 
treated with a slightly excess of 5’-GMP (10 mg/mL in D2O).A shift of H8 proton 
of the purine ring was monitored for ruthenium and osmium complexes by 1H-
NMR, which indicates coordination of the nucleobase over the N7 of the 
heterocycle. For rhodium no such binding was observed. Also no binding via the 
oxygens of the phosphate moiety was monitored by 31P-NMR spectroscopy. 
 
2.2.4. Intercalation Experiments 
 
The possibility of intercalation between the pyridone rings by π-stacking was 
investigated by treating the dimeric compounds 2b–d in CDCL3 with an excess of 
toluene. The experiment was monitored by 1H-NMR, but no signal shifts in the 
aromatic area was observed as it would be expected in case of intercalation. 
                                                      
58
 H. Piotrowski, G. Hilt, A. Schulz, P. Mayer, K. Polborn, K. Severin, Chem. Eur. J. 2001, 7(15), 
3196-3208. 
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3. Experimental Part 
3.1. Equipment, Materials and Methods 
3.1.1. Chemicals 
 
All solvents were dried and distilled prior to use. 
 
2,3-DHP (Aldrich), bromo ethyl acetate (Fischer), morpholine (Fluka), aqueous 
formaldehyde solution (30%, Merck), cyclohexene (Fluka), palladium on 
activated charcoal (10%, Aldrich), sodium methoxide (Aldrich), α-terpinene 
(Acros), ruthenium(III) chloride trihydrate (Johnson Matthey), osmiumtetroxide 
(Degussa), rhodium(III) chloride trihydrate (Johnson Matthey), hydrazine 
hydrochloride (Fluka), pentamethylcyclopentadiene (95%, Aldrich), lithium 
chloride (Aldrich), sodium chloride, potassium chloride (Aldrich) deuterated 
sodium hydroxide (euriso-top) and deuterated nitirc acid (euriso-top), guanosine 
monophosphate (Aldrich) were purchased and used without further purification. 
3.1.2. Equipment 
NMR spectra were recorded at 25 °C using a Bruker FT-NMR spectrometer 
Avance IIITM 500 MHz Proton NMR spectra were measured at 500.10 MHz, 13C-
NMR spectra at 125.75 MHz in deuterated solvents. 2D NMR spectra were 
measured using a gradient-enhanced mode. Elemental analyses were carried 
out with a Perkin Elmer 2400 CHN elemental analyzer at the microanalytical 
laboratory of the University of Vienna. Melting Points were determined by using a 
Büchi Melting Point B-540. The X-ray diffraction measurement was performed 
with single crystals of 2b, 4c, 4d, 5d and 8b on a Bruker X8 APEX II CCD 
diffractometer at 100 K. A Bruker esquire 3000 ion trap mass spectrometer with 
an orthogonal ESI source was used for ESI-MS measurements. The pD values 
were determined directly in the NMR tubes using a pH-meter Eco Scan pH6 
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equipped with a glass microcombination pH electrode (Orion 9826BN) that was 
calibrated with standard buffer solutions of pH 4.00, 7.00 and 10.00. 
3.1.3. Procedures to determine Sensitivity to Alkaline Metal Ions 
Method A 
Complex (1 mg) was solved in 1 mL of CDCl3, 1 mL of a 10 mM MCl solution (M 
= lithium, sodium, potassium) in D2O was added and stirred for 24 hours. The 
aqueous phase and the organic phase were measured by 1H-NMR. 
 
Method B 
Complex (1 mg) was solved in 1 mL of a 0.1 M LiCl solution in CD3OD, stirred for 
15 hours and measured by 1H-NMR. 
3.2. General Procedures 
3.2.1. General Procedure for the Ester Hydrolysis 
Pyridone ester (1 eq.) was stirred in sodium hydroxide (4M, 2.36 eq.) for 
45 minutes which yielded a clear solution. Hydrochloric acid (30%) was added 
dropwise at 0 °C until a faint precipitate appeared. Two more drops were added 
and the suspension was stored at 4 °C for 2 hours. The colorless solid was 
filtered off, washed with ice-cold water and dried in vacuo. 
3.2.2. General Procedure for Pyridone-based Metal Complexes 
Pyridone ligand (1.1 eq) and sodium methoxide (1.1 eq for ester, 2.5 eq for acid) 
were dissolved in 10 mL dry methanol and stirred for 1 hour under an argon 
atmosphere to give a clear solution. Precursor complex (1.0 eq) was added in 
one portion and the reaction mixture was stirred for further 4–16 hours at room 
temperature. The solution was concentrated to dryness and the residue was 
extracted with dichloromethane, filtered and concentrated to a final volume of 
about 3 mL. Upon addition of n-hexane or diethyl ether the desired product was 
precipitated, isolated by filtration and dried in vacuo. 
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3.3. Synthesis of Precursor Metal Complexes 
 
3.3.1. Synthesis of Bis[dichlorido(η6-p-cymene)ruthenium(II)] - p1 
 
 
 
Synthesis: 
α-Terpinene (12.5 mL, 77 mmol) was added to a solution of the RuCl3*3H2O 
(2.00 g, 7.6 mmol) in dry EtOH (75 mL) and the reaction mixture was refluxed for 
4 h. The mixture was cooled to room temperature, the volume was reduced to 
30 mL and diethyl ether (40 mL) was added whereas precipitation occurred. The 
obtained red solid was filtered off, washed with diethyl ether (3 x 10 mL) and 
dried in vacuum. 
 
Yield: 2.14 g (92%) 
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3.3.2. Synthesis of Bis[dichlorido(η6-p-cymene)osmium(II)] - p2 
 
 
 
Synthesis: 
Hydrochloric acid (50 mL) was added to hydrazine-hydrochloride (840 mg, 
8 mmol) in a 100 mL round-bottom flask, equipped with a CaCl2 drying tube. 
Afterwards, osmiumtetroxide (2.00 g) was added and the mixture was stirred for 
2 weeks under light exposure. 
After this time the red solution was filtered and the solvent was evaporated. The 
residue was dissolved in EtOH (20 mL) and concentrated to dryness (3x) and 
finally three times with dry EtOH. The obtained red oil was flushed 3 times with 
argon and dissolved in dry EtOH (40 mL). α-Terpinene was added to the red 
solution and refluxed for three days with exclusion of light and under an argon 
atmosphere. 
After that, the solution was allowed to cool to room temperature and stored at       
-20 °C for 2 more days. The formed orange solid was filtered off and washed with 
dry EtOH (3x 3 mL) and in vacuo. 
 
Yield: 2.42 g (79%) 
|55 
 
3.3.3. Synthesis of Bis[dichlorido(η5-pentamethylcyclopentadiene) 
 rhodium(III)] - p3 
 
 
 
Synthesis: 
 
Pentamethylcyclopentadiene (1.00 mL, 7.20 mmol) was added to a solution of 
the RhCl3·3H2O (1.02 g, 3.90 mmol) in dry methanol (25 mL) and the reaction 
mixture was refluxed for 24 h. After cooling the mixture to 4 °C, the so formed red 
precipitate was filtered off, washed with diethyl ether (3 x 10 mL) and dried in 
vacuo. 
 
Yield: 0.98 g (82%) 
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3.4. Ligand Synthesis 
3.4.1. 1-Ethoxycarbonylmethyl-3-hydroxy-2(1H)-pyridone - 1a 
 
 
 
Synthesis: 
Ethyl bromoacetate (75 mL, 0.66 mol) and 2,3-DHP (15.0 g, 0.13 mol) were 
refluxed under an argon atmosphere for 24 hours. Afterwards the brown solution 
was allowed to cool to room temperature and then stored at 4 °C for 24 hours. 
The formed solid was filtered off and recrystallized from EtOH (96%) in the 
presence of charcoal. The colorless product was separated by filtration, washed 
with cold EtOH and dried in vacuo. 
 
Yield: 8.01 g (31% of theory, 49% of literature54) 
 
Melting point: 142 – 143 °C 
 
Elemental analysis: calculated for C9H11NO4·0.25H2O 
 
1a C[%] H[%] N[%] 
calculated 53.59 5.75 6.94 
found 53.80 5.53 7.13 
∆ 0.21 0.22 0.19 
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NMR-spectroscopy: 
 
 
 
1H NMR (500 MHz, d6-DMSO): δ = 1.22 (t, 3J(H,H) = 7 Hz, 3H, H5'), 4.15 (q, 
3J(H,H) = 7 Hz, 2H, H4'), 4.72 (s, 2H, H1'), 6.13 (dd, 3J(H,H) = 7 Hz, 3J(H,H) = 
7 Hz, 1H, H5), 6.74 (dd, 3J(H,H) = 7 Hz, 4J(H,H) = 2 Hz, 1H, H4), 6.87 (dd, 
3J(H,H) = 7 Hz, 4J(H,H) = 2 Hz, 1H, H6), 9.12 (s, 1H, Pyr-OH) ppm. 
 
13C NMR (75 MHz, d6-DMSO): δ = 14.5 (C5'), 50.7 (C1'), 61.4 (C4'), 105.6 (C5), 
115.8 (C4), 129.3 (C6), 147.2 (C3), 158.4 (C2), 168.5 (C2') ppm. 
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3.4.2. 1-Carboxylmethyl-3-hydroxy-2(1H)-pyridone - 2a 
 
 
 
Synthesis: 
The synthesis was performed according to the general procedure for the ester 
hydrolysis using 5 g (25.4 mmol) of compound 1a. 
 
Yield: 3.38 g (80% of theory, 96% of literature55) 
 
Melting Point: 213–215 °C 
 
Elemental analysis: calculated for C7H7NO4 
 
2a C[%] H[%] N[%] 
calculated 49.71 4.17 8.28 
found 49.38 4.16 8.20 
∆ 0.33 0.01 0.08 
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NMR-spectroscopy: 
 
 
 
1H NMR (500 MHz, d6-DMSO): δ = 4.64 (s, 2H, H1'), 6.10 (dd, 3J(H,H) = 7 Hz, 
3J(H,H) = 7 Hz, 1H, H5), 6.73 (dd, 3J(H,H) = 6 Hz, 4J(H,H) = 2 Hz, 1H, H4), 7.14 
(dd, 3J(H,H) = 5 Hz, 4J(H,H) = 2 Hz, 1H, H6), 9.07 (s, 1H, Pyr-OH), 12.98 (brs, 
1H, COOH) ppm. 
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3.4.3. 1-Ethyoxycarbonylmethyl-3-hydroxy-4-morpholinomethyl-2(1H)-
 pyridone - 1i 
 
Synthesis: 
To an aqueous formaldehyde solution (35%, 5.70 g, 57.8 mmol) morpholine 
(5.02 mL, 57.8 mmol) was added slowly at ca. 0° C. The solution was stirred for 
15 minutes at 0 °C and additionally 15 minutes at room temperature. The formed 
mannich reagent was added dropwise to compound 1a (3.80 g, 19.3 mmol) in 
30 mL EtOH (96%). The mixture was stirred for 24 hours yielding a clear solution. 
The reaction mixture was stored at 4 °C whereas the product precipitated. The 
crude product was filtered and recrystallized from EtOH (96%). The desired 
product was isolated as a colorless solid by filtration and, dried in vacuo. 
 
Yield: 4.36 g (76% of theory, 96% of literature55) 
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NMR-spectroscopy:  
 
 
 
1H NMR (500 MHz, d6-DMSO): δ = 1.22 (t, 3J(H,H) = 7 Hz, 3H, H5'), 2.39 (t, 
3J(H,H) = 4 Hz, 4H, H3''), 3.39 (s, 2H, H1''), 3.36 (t, 3J(H,H) = 5 Hz, 4H, H4''), 
4.15 (q, 3J(H,H) = 7 Hz, 2H, H4'), 4.71 (s, 2H, H1'), 6.22 (d, 3J(H,H) = 7 Hz, 1H, 
H5), 7.12 (d, 3J(H,H) = 7 Hz, 1H, H6), 9.17 (brs, 1H, Pyr-OH) ppm. 
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3.4.4. 1-Ethyoxycarbonylmethyl-3-hydroxy-4-methyl-2-(1H)-pyridone - 
 3a 
 
 
Synthesis: 
Compound 1i (4 g, 13.5 mmol) was suspended in dry EtOH (32 mL) and 
cyclohexene (65 mL). After 30 minutes Pd/C catalyst (10%, 0.8 g) was added 
and the mixture was refluxed for 24 hours. The catalyst was filtered off and the 
solvent was removed under reduced pressure to give a colorless solid, which 
was recrystallized from dry EtOH yielding colorless needles.  
 
Yield: 1.96 g (69% of theory, 95% of literature55) 
 
Melting point: 158 – 160 °C 
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NMR-spectroscopy:  
 
 
 
1H NMR (500 MHz, d6-DMSO): δ = 1.22 (t, 3J(H,H) = 7 Hz, 3H, H5'), 2.04 (s, 3H, 
H1''), 4.14 (q, 3J(H,H) = 7 Hz, 2H, H4'), 4.69 (s, 2H, H1'), 6.08 (d, 3J(H,H) = 7 Hz, 
1H, H5), 7.07 (d, 3J(H,H) = 7 Hz, 1H, H6), 8.73 (brs, 1H, Pyr-OH) ppm. 
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3.4.5. 1-Carboxylmethyl-3-hydroxy-2(1H)-4-methyl-pyridone - 4a 
 
 
 
Synthesis: 
Synthesis was performed according to the general procedure for the ester 
hydrolysis using 448 mg (2.12 mmol) of compound 1d. 
 
Yield: 299 mg (77% of theory, 96% of literature55) 
 
Melting point: 245 – 247 °C 
 
Elemental analysis: calculated for C8H9NO4 
 
4a C[%] H[%] N[%] 
calculated 51.69 5.04 7.57 
found 51.50 4.51 7.54 
∆ 0.19 0.53 0.03 
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NMR-spectroscopy:  
 
 
 
1H NMR (500 MHz, d6-DMSO): δ = 2.03 (s, 3H, H1''), 4.61 (s, 2H, H1'), 6.05 (d, 
3J(H,H) = 7 Hz, 1H, H5), 7.06 (d, 3J(H,H) = 7 Hz, 1H, H6), 8.68 (s, 1H, Pyr-OH), 
12.95 (brs, 1H, -COOH) ppm. 
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3.4.6. 1-Ethoxycarbonylethyl-3-hydroxy-2(1H)-pyridone - 5a 
 
 
 
Synthesis: 
Anhydrous KF and 2,3-DHP (5 g, 44 mmol) were dissolved in dry acetonitrile 
(60 mL) under an argon-atmosphere. Afterwards, ethyl acrylate (6 mL, 49 mmol) 
was added in one portion to the reaction mixture and the solution was heated to 
reflux for 24 hours. 
In the next step the solvent was removed under reduced pressure, water was 
added to the residue and stirred for 5 minutes. The lightly green, brown solid was 
filtered off and washed with water yielding a beige powder.  
 
Yield: 8.34 g (90%) 
 
Melting point: 97 – 98 °C 
 
Elemental analysis: calculated for C10H13NO4 
 
5a C[%] H[%] N[%] 
calculated 56.86 6.20 6.63 
found 56.51 6.00 6.63 
∆ 0.35 0..20 0 
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NMR-spectroscopy:  
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1H NMR (500 MHz, d6-DMSO): δ = 1.16 (t, 3J(H,H) = 7 Hz, 3H, H6'), 2.75 (t, 
3J(H,H) = 7 Hz, 2H, H2'), 4.06 (q, 3J(H,H) = 7 Hz, 2H, H5'), 4.13 (t, 3J(H,H) = 
7 Hz, 2H, H1'), 6.09 (dd, 3J(H,H) = 7 Hz, 3J(H,H) = 7 Hz, 1H, H5), 6.69 (dd, 
3J(H,H) = 6 Hz, 4J(H,H) = 2 Hz, 1H, H4), 7.13 (dd, 3J(H,H) = 5 Hz, 4J(H,H) = 2 Hz, 
1H, H6), 9.01 (brs, 1H, Pyr-OH) ppm. 
 
13C NMR (75 MHz, d6-DMSO): δ = 14.5 (C6'), 33.4 (C2'), 45.7 (C1'), 60.7 (C5'), 
105.7 (C5), 115.2 (C4), 128.9 (C6), 147.1 (C3), 158.2 (C2), 171.2 (C3) ppm. 
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3.4.7. 1-Carboxylethyl-3-hydroxy-2(1H)-pyridone - 6a 
 
 
 
Synthesis: 
Synthesis was performed according to the general procedure for the ester 
hydrolysis using 600 mg (2.80 mmol) of compound 5a. 
 
Yield: 445 mg (87%) 
 
Melting point: 192 – 193 °C 
 
Elemental analysis: calculated for C8H9NO4 
 
6a C[%] H[%] N[%] 
calculated 52.46 4.95 7.65 
found 52.35 4.85 7.60 
∆ 0.11 0.10 0.05 
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NMR-spectroscopy:  
 
 
 
1H NMR (500 MHz, d6-DMSO): δ = 2.68 (t, 3J(H,H) = 7 Hz, 2H, H2'), 4.10 (t, 
3J(H,H) = 7 Hz, 2H, H1'), 6.09 (dd, 3J(H,H) = 7 Hz, 3J(H,H) = 7 Hz, 1H, H5), 6.70 
(dd, 3J(H,H) = 6 Hz, 4J = 2 Hz, 1H, H4), 7.14 (dd, 3J(H,H) = 5 Hz, 4J(H,H) = 2 Hz, 
1H, H6), 9.00 (s, 1H, Pyr-OH), 12.43 (s, 1H, -COOH) ppm. 
 
13C NMR (75 MHz, d6-DMSO): δ = 33.4 (C2'), 45.8 (C1'), 105.6 (C5), 115.2 (C4), 
129.0 (C6), 147.1 (C3), 158.1 (C2), 172.7 (C3') ppm. 
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3.4.8. 1-Ethyoxycarbonylethyl-3-hydroxy-4-morpholinomethyl-2(1H)-
 pyridone - 5i 
 
 
Synthesis: 
To an aqueous formaldehyde-solution (35%, 5.70 g, 57.8 mmol) morpholine 
(5.02 mL, 57.8 mmol) was added slowly at 0 °C. The solution was stirred for 
15 minutes at 0 °C and an additional 15 minutes at room temperature. The 
formed mannich reagent was added dropwise to compound 5a (3.80 g, 
19.3 mmol) in 30 mL EtOH (96%). The mixture was stirred for 24 hours, during 
that time it became a clear solution. The solvent was removed under reduced 
pressure, water was added and the solid was filtered off and washed with water 
yielding a colorless powder. 
 
Yield: 3.59 g (60%)  
 
Melting point: 113 – 115°C 
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Elemental analysis: calculated for C15H22N2O5 
 
 C[%] H[%] N[%] 
calculated 58.05 7.15 9.03 
found 58.01 7.24 9.02 
∆ 0.04 0.09 0.01 
 
NMR-spectroscopy:  
 
 
 
1H NMR (500 MHz, d6-DMSO): δ = 1.16 (t, 3J(H,H) = 7 Hz, 3H, H6'), 2.37 (t, 
3J(H,H) = 4 Hz, 4H, H3''), 2.75 (t, 3J(H,H) = 7 Hz, 2H, H2'), 3.36 (s, 1H, H1''), 3.58 
(t, 3J(H,H) = 5 Hz, 4H, H4''), 4.06 (q, 3J(H,H) = 7 Hz, 2H, H5'), 4.12 (t, 3J(H,H) = 
7 Hz, 2H, H1'), 6.18 (d, 3J(H,H) = 7 Hz, 1H, H5), 7.11 (d, 3J(H,H) = 7 Hz, 1H, H6), 
9.04 (s, 1H, Pyr-OH) ppm. 
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3.4.9. 1-Ethyoxycarbonylethyl-3-hydroxy-4-methyl-2-(1H)-pyridone - 
 7a 
N O
OH
N
O
OO
Pd/C, EtOH
N O
OH
O O
 
 
Synthesis: 
Compound 5i (4.00 g, 12.9 mmol) was suspended in dry EtOH (25 mL) and 
cyclohexene (50 mL). After 30 minutes of stirring the Pd/C catalyst (10%, 1.28 g) 
was added and the mixture was refluxed for 24 hours. The catalyst was filtered 
off and solvent was removed under reduced pressure yielding a colorless solid, 
which was washed with water and dried in vacuo.  
 
Yield: 2.26 g (78%) 
 
Melting point: 108 – 109 °C 
 
Elemental analysis: calculated for C11H15NO4 
 
7a C[%] H[%] N[%] 
calculated 58.66 6.71 6.22 
found 58.53 6.69 6.16 
∆ 0.13 0.02 0.06 
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NMR-spectroscopy:  
 
 
 
1H NMR (500 MHz, d6-DMSO): δ = 1.17 (t, 3J(H,H) = 7 Hz, 3H, H6'), 2.01 (s, 3H, 
H1''), 2.74 (t, 3J(H,H) = 7 Hz, 2H, H2'), 4.06 (q, 3J(H,H) = 5 Hz, 2H, H5'), 4.11 (t, 
3J(H,H) = 7 Hz, 2H, H1'), 6.04 (d, 3J(H,H) = 7 Hz, 1H, H5), 7.06 (d, 3J(H,H) = 
7 Hz, 1H, H6), 8.82 (brs, 1H, Pyr-OH) ppm. 
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3.4.10. 1-Carboxylethyl-3-hydroxy-2(1H)-4-methyl-pyridone - 8a 
 
 
 
Synthesis: 
The synthesis was performed according to the general procedure for the ester 
hydrolysis using 1.00 g (4.40 mmol) of compound 7a. 
 
Yield: 0.662 g (76%) 
 
Melting point: 165 – 166 °C 
 
Elemental analysis: calculated for C9H11NO4 
 
8a C[%] H[%] N[%] 
calculated 54.82 5.62 7.10 
found 54.71 5.43 6.97 
∆ 0.11 0.19 0.13 
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NMR-spectroscopy:  
 
 
 
1H NMR (500 MHz, d6-DMSO): δ = 2.01 (s, 3H, H1''), 2.67 (t, 3J(H,H) = 7 Hz, 2H, 
H2'), 4.07 (t, 3J(H,H) = 7 Hz, 2H, H1'), 6.04 (d, 3J(H,H) = 7 Hz, 1H, H5), 7.07 (d, 
3J(H,H) = 7 Hz, 1H, H6), 8.62 (s, 1H, Pyr-OH), 12.41 (brs, 1H, -COOH) ppm. 
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3.5. Synthesis of Pyridone-based Metal Complexes 
3.5.1. [Chlorido(η6-p-cymene){N-[(ethylcarbonyl)methyl]-3-oxo-κO-2-
 (1H)-pyridonato-κO}ruthenium(II)] - 1b 
 
 
Synthesis: 
The synthesis was performed according to the general procedure using 120 mg 
(0.196 mmol) of ruthenium precursor p1, 85 mg (0.431 mmol) of compound 1a 
and 28 mg (0.49 mmol) of NaOMe. The resolved crude product was precipitated 
by addition of Et2O (20 mL). 
 
Yield: 170 mg (92%) 
 
Melting point: >205 °C (decomposition 
 
Water solubility: 5.16 mg/mL 
 
Elemental analysis: calculated for C19H24ClNO4Ru 
 
1b C[%] H[%] N[%] 
calculated 48.87 5.18 3.00 
found 48.56 5.26 2.97 
∆ 0.31 0.08 0.03 
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NMR-spectroscopy:  
 
 
 
1H NMR (500 MHz, CDCl3): δ = 1.32–1.36 (m, 9H, Hf, H5'), 2.31 (s, 3H, Hg), 
2.87–2.93 (m, 1H, He), 4.23–4.31 (m, 3H, H4', H1'), 5.15 (d, 2J(H,H) = 17 Hz, 1H, 
H1'), 5.31 (d, 3J(H,H) = 6 Hz, 1H, Hb), 5.32 (d, 3J(H, H) = 6 Hz, 1H, Hb), 5.52 (d, 
3J(H, H) = 6 Hz, 1 H, Hc), 5.53 (d, 3J(H, H) = 6 Hz, 1 H, Hc), 6.28 (dd, 3J(H,H) = 
7 Hz, 3J(H,H) = 7 Hz, 1H, H5), 6.40 (dd, 3J(H,H) = 7 Hz, 4J(H,H) = 1 Hz, 1H, H4), 
6.69 (dd, 3J(H,H) = 8 Hz, 4J(H,H) = 1 Hz, 1H, H6) ppm.  
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3.5.2. [Chlorido(η6-p-cymene){N-[(ethylcarbonyl)methyl]-3-oxo-κO-2-
 (1H)-pyridonato-κO}osmium(II)] - 1c 
 
 
 
Synthesis: 
The synthesis was performed according to the general procedure using 100 mg 
(0.16 mmol) of osmium precursor p2, 67 mg (0.34 mmol) of compound 1a and 
22 mg (0.37 mmol) of NaOMe. The resolved crude product was precipitated by 
addition of n-hexane (20 mL). 
 
Yield: 105 mg (59%) 
 
Melting point: >144 °C (decomposition) 
 
Water solubility: 0.26 mg/mL 
 
Elemental analysis: calculated for: C19H24ClNO4Os·0.1C4H10O 
 
1c C[%] H[%] N[%] 
calculated 41.35 4.47 2.49 
found 41.54 4.39 2.71 
∆ 0.19 0.08 0.22 
 
80|   
 
NMR-spectroscopy:  
 
 
 
1H NMR (500 MHz, CDCl3) δ = 1.29–1.35 (m, 9H, Hf, H5'), 2.34 (s, 3H, Hg), 
2.71–2.78 (m, 1H, He), 4.25–4.35 (m, 3H, H4', H1'), 5.15 (d, 2J(H,H) = 17 Hz, 1H, 
H1'), 5.77 (d, 3J(H,H) = 6 Hz, 1H, Hb), 5.84 (d, 3J(H,H) = 5 Hz, 1H, Hb), 6.02 (d, 
3J(H,H) = 5 Hz, 1H, Hc), 6.06 (d, 3J(H,H) = 6 Hz, 1H, Hc), 6.33 (dd, 3J(H,H) = 
7 Hz, 3J(H,H) = 7 Hz, 1H, H5), 6.46 (dd, 3J(H,H) = 7 Hz, 4J(H,H) = 1 Hz, 1H, H4), 
6.75 (dd, 3J(H,H) = 8 Hz, 4J(H,H) = 2 Hz, 1H, H6) ppm. 
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3.5.3. [Chlorido(η5-pentamethylcyclopentadiene){N-[(ehtylcarbonyl)-
 methyl)]-3-oxo-κO-2-(1H)-pyridonato-κO}rhodium(III)] - 1d 
 
 
Synthesis: 
The synthesis was performed according to the general procedure using 100 mg 
(0.16 mmol) of rhodium precursor p3, 70 mg (0.36 mmol) of compound 1a and 
35 mg (0.64 mmol) of NaOMe. The resolved crude product was precipitated by 
addition of Et2O (20 mL). 
 
Yield: 78 mg (54%) 
 
Melting point: >198 °C (decomposition) 
 
Water solubility: 11.25 mg/mL 
 
Elemental analysis: calculated for C19H25ClNO4Rh 
 
1d C[%] H[%] N[%] 
calculated 48.39 5.39 2.97 
found 48.44 5.06 2.94 
∆ 0.05 0.33 0.03 
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NMR-spectroscopy:  
 
 
 
1H NMR (500 MHz, d4-CD3OD): δ = 1.33 (t, 3H, 3J(H,H) = 7 Hz, H5'), 1.69 (s, 
15H, Hb), 4.30 (q, 3J(H,H) = 7Hz, 2H, H4'), 4.86 (s, 2H, H1'), 6.37 (dd, 3J(H,H) = 
7 Hz, 3J(H,H) = 7 Hz, 1H, H5), 6.66 (d, 3J(H,H) = 7 Hz, 1H, H4), 6.81 (d, 3J(H,H) 
= 7 Hz, 1H, H6) ppm. 
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3.5.4. Bis[(η6-p-cymene){N-[(carboxyl-κO)methyl]-3-oxo-κO-2-(1H)-
 pyridonato-κO}ruthenium(II)] - 2b 
 
 
Synthesis: 
The synthesis was performed according to the general procedure using 245 mg 
(0.40 mmol) of ruthenium precursor p1, 150 mg (0.88 mmol) of compound 2a 
and 102 mg (1.80 mmol) of NaOMe. The resolved crude product was precipitated 
by addition of Et2O (20 mL). 
 
Yield: (45%) 
 
Melting point: >188 °C (decomposition) 
 
Water solubility: 5.77 mg/mL 
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Elemental analysis: calculated for C34H38N2O8Ru2·2H2O 
 
2b C[%] H[%] N[%] 
calculated 48.57 5.03 3.33 
found 48.54 4.79 3.43 
∆ 0.03 0.24 0.10 
 
NMR-spectroscopy:  
 
 
1H NMR (500 MHz, CDCl3): δ = 1.28–1.33 (m, 6H, Hf), 2.26 (s, 3H, Hg), 2.87–
2.92 (m, 1H, He), 3.89 (d, 2J(H,H) = 16 Hz, 1H, H1'), 5.12 (d, 2J(H,H) = 16 Hz, 
1H, H1'), 5.40 (d, 3J(H,H) = 6 Hz, 1H, Hb), 5.57 (d, 3J(H,H) = 6 Hz, 1H, Hb), 5.72 
(d, 3J(H,H) = 6 Hz, 1H, Hc), 5.78 (d, 3J(H,H) = 6 Hz, 1H, Hc), 5.85 (dd, 3J(H,H) = 
7 Hz, 3J(H,H) = 7 Hz, 1H, H5), 6.19 (dd, 3J(H,H) = 8 Hz, 4J(H,H) = 1 Hz, 1H, H4), 
6.25 (dd, 3J(H,H) = 7 Hz, 4J(H,H) = 1 Hz, 1H, H6) ppm. 
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3.5.5. Bis[(η6-p-cymene){N-[(carboxyl-κO)methyl]-3-oxo-κO-2-(1H)-
 pyridonato-κO}osmium(II)] - 2c 
 
 
Synthesis: 
The synthesis was performed according to the general procedure using 119 mg 
(0.15 mmol) of osmium precursor p2, 61 mg (0.36 mmol) of compound 2a and 
51 mg (0.89 mmol) of NaOMe. The resolved crude product was precipitated by 
addition of n-hexane (20 mL). 
 
Yield: 84 mg (57%) 
 
Melting point: >170 °C (decomposition) 
 
Water solubility: 1.37 mg/mL 
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Elemental analysis: calculated for C34H38N2O8Os2·0.25C4H10O 
 
2c C[%] H[%] N[%] 
calculated 41.97 4.07 2.80 
found 42.23 4.29 2.71 
∆ 0.26 0.22 0.09 
 
NMR-spectroscopy:  
 
 
1H NMR (500 MHz, CD3OD): δ = 1.29–1.34 (m, 6H, Hf), 2.30 (s, 3H, Hg), 2.72–
2.77 (m, 1H, He), 4.18 (d, 2J(H,H) = 16 Hz, 1H, H1'), 4.94 (d, 2J(H,H) = 16 Hz, 
1H, H1'), 5.92 (d, 3J(H,H) = 5 Hz, 1H, Hb), 5.95 (d, 3J(H,H) = 5 Hz, 1H, Hb), 6.09 
(dd, 3J(H,H) = 7 Hz, 3J(H,H) = 7 Hz, 1H, H5), 6.24 (d, 3J(H,H) = 5 Hz, 1H, Hc), 
6.28 (d, 3J(H,H) = 5 Hz, 1H, Hc), 6.36 (dd, 3J(H,H) = 8 Hz, 4J(H,H) = 1 Hz, 1H, 
H4), 6.52 (dd, 3J(H,H) = 7 Hz, 4J(H,H) = 1 Hz, 1H, H6) ppm. 
 
13C NMR (125.75 MHz, CD3OD): δ = 17.7 (Cg), 21.5 (Cf), 22.4 (Cf), 31.8 (Ce), 
51.8 (C1'), 67.0 (Cb), 67.1 (Cb), 70.5 (Cc), 71.1 (Cc), 83.8 (Ca), 87.7 (Cd), 111.6 
(C5), 117.5 (C6), 124.2 (C4), 158.9 (C2'), 167.3 (C3), 172.9 (C2) ppm. 
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3.5.6. Bis[(η5-pentamethylcyclopentadiene){N-[(ethoxycarbonyl)-
 methyl]-3-oxo-κO-2-(1H)-pyridonato-κO}rhodium(III)] - 2d 
 
Synthesis: 
The synthesis was performed according to the general procedure using 100 mg 
(0.16 mmol) of rhodium precursor p3, 57 mg (0.34 mmol) of compound 2a and 
48 mg (0.85 mmol) of NaOMe. The resolved crude product was precipitated by 
addition of n-hexane (20 mL). 
 
Yield: 90 mg (69%) 
 
Melting point: >185 °C (decomposition) 
 
Water solubility: 15.00 mg/mL 
 
Mass spectrometry: m/z =  428 (C17H20NO4Rh + Na+) 
    
833 (C34H40N2O8Rh2 + Na+) 
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NMR-spectroscopy:  
 
 
1H NMR (500 MHz, d4-CD3OD): δ = 1.71 (s, 15H, Hb), 4.60 (brs, 2H, H1'), 6.35 
(dd, 3J(H,H) = 7 Hz, 3J(H,H) = 7 Hz, 1H, H5), 6.68 (d, 3J(H,H) = 8 Hz, 1H, H4), 
6.82 (d, 3J(H,H) = 7 Hz, 1H, H6) ppm. 
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3.5.7. [Chlorido(η6-p-cymene){N-[(ethylcarbonylmethyl]-3-oxo-κO-4-
 methyl-2-(1H)-pyridonato-κO}ruthenium(II)] - 3b 
 
 
 
Synthesis: 
The synthesis was performed according to the general procedure using 122 mg 
(0.20 mmol) of ruthenium precursor p1, 85 mg (0.40 mmol) of compound 3a and 
25 mg (0.44 mmol) of NaOMe. A red solid was formed after 3 hours reaction, 
filtered off, which was washed with methanol and dried in vacuo. 
 
Yield: 110 mg (75%) 
 
Melting point: >205 °C (decomposition) 
 
Water solubility: 1.13 mg/mL 
 
Elemental analysis: calculated for C20H26ClNO4Ru·0.75H2O 
 
3a C[%] H[%] N[%] 
calculated 48.58 5.61 2.83 
found 48.53 5.30 2.89 
∆ 0.05 0.31 0.06 
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NMR-spectroscopy:  
 
 
1H NMR (500 MHz, CDCl3): δ = 1.29–1.35 (m, 9H, Hf, H4'), 2.18 (s, 3H, H1''), 
2.30 (s, 3H, Hg), 2.85–2.91 (m, 1H, He), 4.17–4.29 (m, 3H, H3', H1'), 5.12 (d, 
2J(H,H) = 17 Hz, 1H, H1'), 5.24 (d, 3J(H,H) = 6 Hz, 2H, Hb), 5.48–5.52 (m, 2H, 
Hc), 6.18 (d, 3J(H,H) = 7 Hz, 1H, H5), 6.33 (d, 3J(H,H) = 7 Hz, 1H, H6) ppm.  
 
13C NMR (125.75 MHz, CDCl3): δ = 14.2 (C4'), 15.5 (C1''), 18.5 (Cg), 22.3 (Cf), 
22.4 (Cf), 31.1 (Ce), 51.1 (C1'), 61.8 (C7), 77.1 (Cb), 77.6 (Cb), 80.4 (Cc), 80.6 
(Cc), 95.8 (Ca), 98.5 (Cd), 115.4 (C5), 120.0 (C6), 128.9 (C4), 158.2 (C2'), 164.4 
(C3), 167.2 (C2) ppm. 
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3.5.8. [Chlorido(η6-p-cymene){N-[(ethylcarbonylmethyl]-3-oxo-κO-4-
 methyl-2-(1H)-pyridonato-κO}osmium(II)] - 3c 
 
 
 
Synthesis: 
The synthesis was performed according to the general procedure using 126 mg 
(0.16 mmol) of osmium precursor p2, 72 mg (0.34 mmol) of compound 3a and 
22 mg (0.85 mmol) of NaOMe. The resolved crude product was precipitated by 
addition of Et2O (20 mL). 
 
Yield: 80 mg (44%) 
 
Melting point: >184 °C (decomposition) 
 
Water solubility: <0.1 mg/mL 
 
Elemental analysis: calculated for C20H26ClNO4Os·H2O 
 
3c C[%] H[%] N[%] 
calculated 40.84 4.80 2.38 
found 40.98 4.50 2.32 
∆ 0.14 0.3 0.06 
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NMR-spectroscopy:  
 
 
1H NMR (500 MHz, CDCl3): δ = 1.28–1.35 (m, 9H, Hf, H4'), 2.22 (s, 3H, H1''), 
2.35 (s, 3H, Hg), 2.69–2.77 (m, 1H, He), 3.81 (s, 1H, H1'), 4.26–4.35 (m, 2H, 
H3'), 5.10–5.15 (m, 1H, H1'), 5.76–5.79 (m, 2H, Hb), 6.01–6.04 (m, 2H, Hc), 6.24 
(d, 3J(H,H) = 7 Hz, 1H, H5), 6.40 (d, 3J(H,H) = 7 Hz, 1H, H6) ppm.  
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3.5.9. [Chlorido(η5-pentamethylcyclopentadiene){N-[(ehtylcarbonyl)-
 methyl)]-3-oxo-κO-4-methyl-2-(1H)-pyridonato-κO}rhodium(III)] - 
 3d 
 
 
Synthesis: 
The synthesis was performed according to the general procedure using 100 mg 
(0.16 mmol) of rhodium precursor p3, 76 mg (0.36 mmol) of compound 3a and 
35 mg (0.64 mmol) of NaOMe. The resolved crude product was precipitated by 
addition of n-hexane (20 mL). 
 
Yield: 86 mg (57%) 
 
Melting point: >152 °C (decomposition) 
 
Elemental analysis: calculated for C20H27ClNO4Rh·0.1CH2Cl2 
 
3d C[%] H[%] N[%] 
calculated 49.00 5.55 2.85 
found 49.24 5.17 2.90 
∆ 0.24 0.38 0.05 
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NMR-spectroscopy:  
 
 
1H NMR (500 MHz, d4-CD3OD): δ = 1.34 (t, 3J(H,H) = 7 Hz, 3H, H4'), 1.69 (s, 
15H, Hb), 2.21 (s, 1H, H1''), 3.37 (s, 1H, H1'), 3.83 (s, 1H, H1'), 4.30 (q, 3J(H,H) = 
7 Hz, 2H, H3'), 6.35 (t, 3J(H,H) = 7 Hz, 1H, H5), 6.79 (d, 3J(H,H) = 7 Hz, 1H, H5) 
ppm. 
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3.5.10. Bis[(η6-p-cymene){N-[(carboxyl-κO)ethyl]-3-oxo-κO-4- 
  methyl-2-(1H)-pyridonato-κO}ruthenium(II)]- 4b 
 
 
Synthesis: 
The synthesis was performed according to the general procedure using 153 mg 
(0.25 mmol) of ruthenium precursor p1, 100 mg (0.55 mmol) of compound 4a 
and 81 mg (1.50 mmol) of NaOMe. The resolved crude product was precipitated 
by addition of n-hexane (20 mL). 
 
Yield: 156 mg (75%) 
 
Melting point: >200 °C (decomposition) 
 
Water solubility: 0.59 mg/mL 
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Elemental analysis: calculated for C36H42N2O8Ru2·1.25CH2Cl2 
 
4b C[%] H[%] N[%] 
calculated 47.64 4.78 2.98 
found 47.97 4.74 3.07 
∆ 0.33 0.04 0.09 
 
NMR-spectroscopy:  
 
 
1H NMR (500 MHz, CD3OD): δ = 1.29–1.35 (m, 6H, Hf), 1.98 (s, 3H, H1''), 2.26 
(s, 3H, Hg), 2.85–2.90 (m, 1H, He), 4.02 (d, 2J(H,H) = 16 Hz, 1H, H1'), 4.93 (d, 
2J(H,H) = 16 Hz, 1H, H1'), 5.51 (d, 3J(H,H) = 6 Hz, 1H, Hb), 5.57 (d, 3J(H,H) = 
6 Hz, 1H, Hb), 5.80 (d, 3J(H,H) = 6 Hz, 2H, Hc), 5.87 (d, 3J(H,H) = 7 Hz, 1H, H5), 
6.34 (d, 3J(H,H) = 7 Hz, 1H, H6) ppm.  
 
13C NMR (125.75 MHz, CD3OD): δ = 14.4 (C1''), 17.1 (Cg), 21.1 (Cf), 21.8 (Cf), 
31.1 (Ce), 51.7 (C1'), 77.1 (Cb), 77.4 (Cb), 79.1 (Cc), 79.8 (Cc), 94.1 (Ca), 98.3 
(Cd), 113.1 (C5), 122.6 (C6), 127.9 (C4), 154.8 (C2'), 162.8 (C3), 173.0 (C2) 
ppm. 
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3.5.11. Bis[(η6-p-cymene){N-[(carboxyl-κO)ethyl]-3-oxo-κO-4- 
  methyl-2-(1H)-pyridonato-κO}ruthenium(II)]- 4c 
 
 
Synthesis: 
The synthesis was performed according to the general procedure using 198 mg 
(0.25 mmol) of osmium precursor p2, 100 mg (0.55 mmol) of compound 4a and 
81 mg (1.50 mmol) of NaOMe. The resolved crude product was precipitated by 
addition of Et2O (20 mL). 
 
Yield: 119 mg (47%) 
 
Melting point: >200 °C (decomposition) 
 
Water solubility: <0.1 mg/mL 
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Elemental analysis: calculated for C36H42N2O8Os2·H2O 
 
4c C[%] H[%] N[%] 
calculated 42.01 4.31 2.72 
found 42.19 4.38 2.76 
∆ 0.18 0.07 0.04 
 
NMR-spectroscopy:  
 
 
1H NMR (500 MHz, CD3OD): δ = 1.27–1.30 (m, 6H, Hf), 1.98 (s, 3H, H1''), 2.31 
(s, 3H, Hg), 2.72–2.76 (m, 1H, He), 3.89 (d, 2J(H,H) = 16 Hz, 1H, H1'), 5.08 (d, 
2J(H,H) = 16 Hz, 1H, H1'), 5.79–5.81 (m, 3H, H5, Hb), 6.16–6.22 (m, 3H, Hc, H6) 
ppm.  
 
13C NMR (125.75 MHz, CD3OD): δ = 15.4 (C1''), 18.8 (Cg), 23.0 (Cf), 23.1 (Cf), 
32.0 (Ce), 51.6 (C1'), 66.1 (Cb), 66.5 (Cb), 71.1 (Cc), 71.8 (Cc), 84.3 (Ca), 87.0 
(Cd), 114.0 (C5), 121.4 (C6), 127.0 (C4), 158.0 (C2'), 166.3 (C3), 172.0 (C2) 
ppm. 
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3.5.12. Bis[(η5-pentamethylcyclopentadiene){N-    
  [(ethoxycarbonyl)-methyl]-3-oxo-κO-4-methyl-2-(1H)- 
  pyridonato-κO}rhodium(III)] - 4d 
 
Synthesis: 
The synthesis was performed according to the general procedure using 100 mg 
(0.16 mmol) of rhodium precursor p3, 63 mg (0.34 mmol) of compound 4a and 
35 mg (0.70 mmol) of NaOMe. The resolved crude product was precipitated by 
addition of n-hexane (20 mL). 
 
Yield: 101 mg (75%) 
 
Melting point: >170 °C (decomposition) 
 
Water solubility: 10 mg/mL 
 
100|   
 
NMR-spectroscopy:  
 
 
1H NMR (500 MHz, d4-CD3OD): δ = 1.70 (s, 15H, Hb), 2.20 (s, 3H, H1''), 4.58 
(brs, 2H, H1'), 6.30 (d, 3J(H,H) = 7 Hz, 1H, H5), 6.76 (d, 3J(H,H) = 7 Hz, 1H, H6) 
ppm. 
 
13C NMR (125.75 MHz, d4-CD3OD): δ = 7.3 (Cb), 14.3 (C1''), 53.6 (C1'), 91.8 
(Ca), 113.9 (C5), 122.8 (C6), 129.2 (C4), 156.3 (C2'), 163.7 (C3), 172.3 (C2) 
ppm. 
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3.5.13. [Chlorido(η6-p-cymene){N-[(ethylcarbonyl)ethyl]-3-oxo- 
  κO-2-(1H)-pyridonato-κO}ruthenium(II)] - 5b 
 
 
Synthesis: 
The synthesis was performed according to the general procedure using 245 mg 
(0.4 mmol) of ruthenium precursor p1, 186 mg (0.88 mmol) of compound 5a and 
80 mg (1.40 mmol) of NaOMe. The resolved crude product was precipitated by 
addition of n-hexane (20 mL). 
 
Yield: 88 mg (23%) 
 
Melting point: >101 °C (decomposition) 
 
Water solubility: 1.76 mg/mL 
 
Elemental analysis: calculated for C20H26ClNO4Ru·0.25H2O 
 
5b C[%] H[%] N[%] 
calculated 49.48 5.50 2.89 
found 49.55 5.44 3.02 
∆ 0.07 0.06 0.13 
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NMR-spectroscopy:  
 
 
1H NMR (500 MHz, CDCl3): δ = 1.26 (t, 3J(H, H) = 7 Hz, 3H, H6'), 1.33–1.38 (m, 
6H, Hf), 2.34 (s, 3H, Hg), 2.76–2.81 (m, 1H, H2'), 2.86–2.97 (m, 2H, He, H2'), 
4.16 (q, 2H, 3J(H, H) = 7 Hz, H5'), 4.19–4.32 (m, 2H, H1'), 5.32 (t, 3J(H,H) = 5 Hz, 
2H, Hb), 5.52–5.56 (m, 2H, Hc), 6.21 (dd, 3J(H,H) = 7 Hz, 3J(H,H) = 7 Hz, 1H, 
H5), 6.55 (dd, 3J(H,H) = 7 Hz, 4J(H,H) = 2 Hz, 1H, H4), 6.65 (dd, 3J(H,H) = 8 Hz, 
4J(H,H) = 2 Hz, 1H, H6) ppm.  
 
13C NMR (125.75 MHz, CDCl3): δ = 13.1 (C6'), 17.2 (Cg), 21.2 (Cf), 31.1 (Ce), 
32.7 (C2') 46.5 (C1'), 60.5 (C5'), 76.0 (Cb), 79.5 (Cc), 95.3 (Ca), 99.2 (Cd), 111.8 
(C5), 123.2 (C6), 128.3 (C4), 158.9 (C3'), 165.2 (C3), 170.9 (C2) ppm. 
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3.5.14. [Chlorido(η5-pentamethylcyclopentadiene){N-   
  [(ehtylcarbonyl)ethyl)]-3-oxo-κO-2-(1H)-pyridonato-  
  κO}rhodium(III)] - 5d 
 
 
Synthesis: 
The synthesis was performed according to the general procedure using 100 mg 
(0.16 mmol) of rhodium precursor p3, 72 mg (0.34 mmol) of compound 5a and 
22 mg (0.37 mmol) of NaOMe. The resolved crude product was precipitated by 
addition of n-hexane (20 mL). 
 
Yield: (39%) 
 
Melting point: >164 °C (decomposition) 
 
Water solubility: 8.00 mg/mL 
 
Elemental analysis: calculated for C20H27ClNO4Rh·0.5H2O 
 
5d C[%] H[%] N[%] 
calculated 48.74 5.73 2.84 
found 48.69 5.55 2.88 
∆ 0.05 0.18 0.04 
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NMR-spectroscopy:  
 
 
1H NMR (500 MHz, CDCl3): δ = 1.27 (t, 3J(H,H) = 7 Hz, 3H, H6'), 1.75 (s, 15H, 
Hb), 2.77–2.83 (m, 1H, H2'), 2.92–2.96 (m, 1H, H2'), 4.13–4.19 (m, 3H, H5', H1'), 
4.33–4.39 (m, 1H, H1'), 6.19 (dd, 3J(H,H) = 7 Hz, 3J(H,H) = 7 Hz, 1H, H5), 6.51 
(dd, 3J(H,H) = 7 Hz, 4J = 2 Hz, 1H, H4), 6.61 (dd, 3J(H,H) = 8 Hz, 4J(H,H) = 2 Hz, 
1H, H6) 
 
13C NMR (125.75 MHz, d4-CH3OD): δ = 7.5 (Hb), 13.1 (C6'), 32.8 (C2') 46.4 
(C1'), 60.5 (C5'), 91.9 (Cb), 92.0 (Cb), 111.5 (C5), 117.2 (C6), 122.8 (C4), 159.0 
(C3'), 165.0 (C3), 171.0 (C2) ppm. 
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3.5.15. Bis[([(η6-p-cymene){N-(Carboxyl-ethyl)-3-oxo-κO-2-(1H)- 
  pyridonato-κO}ruthenium(II)] - 6b 
 
Synthesis: 
The synthesis was performed according to the general procedure using 100 mg 
(0.16 mmol) of ruthenium precursor p1, 63 mg (0.34 mmol) of compound 6a and 
41 mg (0.72 mmol) of NaOMe. The resolved crude product was precipitated by 
addition of n-hexane (20 mL). 
 
Yield: 45 mg (34%) 
 
Melting point: >150 °C (decomposition) 
 
Water solubility: 0.66 mg/mL 
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Elemental analysis: calculated for C36H42N2O8Ru2·CH2Cl2 
 
6b C[%] H[%] N[%] 
calculated 48.42 4.83 3.05 
found 48.51 4.91 3.16 
∆ 0.09 0.08 0.11 
 
NMR-spectroscopy:  
 
 
1H NMR (500 MHz, CDCl3): δ = 1.20 (t, 3J(H, H) = 7 Hz, 6H, Hf), 2.24–2.36 (m, 
5H, H2', Hg), 2.74–2.79 (m, 1H, He), 3.92 (td, 1H, 3J(H, H) = 7 Hz, 4J(H,H) = 
2 Hz, H1'), 4.18 (ddd, 2J(H,H) = 13 Hz, 3J(H,H) = 5 Hz, 4J(H,H) = 2 Hz, 1H, H1'), 
5.24 (d, 3J(H,H) = 6 Hz, 1H, Hb), 5.49 (d, 3J(H,H) = 6 Hz, 1H, Hb), 5.58 (d, 
3J(H,H) = 6 Hz, 1H, Hc), 6.10 (d, 3J(H,H) = 6 Hz, 1H, Hc), 6.13 (dd, 3J(H,H) = 
7 Hz, 3J(H,H) = 7 Hz, 1H, H5), 6.55 (dd, 3J(H,H) = 8 Hz, 4J(H,H) = 2 Hz, 1H, H4), 
6.90 (dd, 3J(H,H) = 7 Hz, 4J(H,H) = 1 Hz, 1H, H6) ppm.  
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3.5.16. Bis[([(η5-pentamethylcyclopentadiene){N-   
  [(ethoxycarbonyl)ethyl]-3-oxo-κO-2-(1H)-pyridonato-  
  κO}rhodium(III)] - 6d 
 
 
Synthesis: 
The synthesis was performed according to the general procedure using 100 mg 
(0.16 mmol) of ruthenium precursor p3, 62 mg (0.34 mmol) of compound 6a and 
41 mg (0.72 mmol) of NaOMe. The resolved crude product was precipitated by 
addition of n-hexane (20 mL). 
 
Yield: 71 mg (53%) 
 
Melting point: >103 °C (decomposition) 
 
Water solubility: 4.17 mg/mL 
 
Mass spectrometry: m/z =  420 (C18H22NO4Rh) 
    442 (C18H22NO4Rh + Na+) 
    
839 (C36H44N2O8Rh2) 
    861 (C36H44N2O8Rh2 + Na+) 
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NMR-spectroscopy:  
 
 
1H NMR (500 MHz, d4-CD3OD): δ = 1.74 (s, 15H, Hb), 2.68 (t, 3J(H,H) = 7 Hz, 
2H, H2'), 4.29 (brs, 2H, H1'), 6.32 (dd, 3J(H,H) = 7 Hz, 3J(H,H) = 7 Hz, 1H, H5), 
6.66 (d, 3J(H,H) = 7 Hz, 1H, H4), 6.90 (d, 3J= 6 Hz, 1H, H6) ppm. 
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3.5.17. [Chlorido(η6-p-cymene){N-[(ethylcarbonyl)ethyl]-3-oxo- 
  κO-4-methyl-2-(1H)-pyridonato-κO}ruthenium(II)] - 7b 
 
 
 
Synthesis: 
The synthesis was performed according to the general procedure using 245 mg 
(0.4 mmol) of ruthenium precursor p1, 198 mg (0.88 mmol) of compound 7a and 
80 mg (1.40 mmol) of NaOMe. The resolved crude product was precipitated by 
addition of Et2O (20 mL). 
 
Yield: 212 mg (54%) 
 
Melting point: >133 °C (decomposition) 
 
Water solubility: 0.60 mg/mL 
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Elemental analysis: calculated for C21H28NO4ClRu·0.4CH2Cl2 
 
7b C[%] H[%] N[%] 
calculated 48.59 5.49 2.65 
found 48.33 5.45 3.11 
∆ 0.26 0.04 0.46 
 
NMR-spectroscopy:  
 
 
1H NMR (500 MHz, CDCl3): δ = 1.27 (t, 3J(H, H) = 7 Hz, 3H, H6'), 1.35–1.37 (m, 
6H, Hf), 2.17 (s, 3H, H1''), 2.36 (s, 3H, Hg), 2.75–2.81 (m, 1H, H2'), 2.90–2.96 
(m, 2H, He, H2'), 4.14–4.21 (m, 3H, H5', H1'), 4.25–4.30 (m, 1H, H1'), 5.26–5.29 
(m, 2H, Hb), 5.54–5.55 (m, 2H, Hc), 6.13 (d, 3J(H,H) = 7 Hz, 1H, H5), 6.49 (d, 
3J(H,H) = 7 Hz, 1H, H6) ppm.  
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3.5.18. [Chlorido(η6-p-cymene){N-[(ethylcarbonyl)ethyl]-3-oxo- 
  κO-4-methyl-2-(1H)-pyridonato-κO}osmium(II)] - 7c 
 
 
 
Synthesis: 
The synthesis was performed according to the general procedure using 126 mg 
(0.16 mmol) of osmium precursor p2, 77 mg (0.34 mmol) of compound 7a and 
22 mg (0.39 mmol) of NaOMe. The resolved crude product was precipitated by 
addition of n-hexane (20 mL). 
 
Yield: 48 mg (51%) 
 
Melting point: >142 °C (decomposition) 
 
Elemental analysis: calculated for C21H28NO4ClOs 
 
7b C[%] H[%] N[%] 
calculated 43.18 4.83 2.40 
found 43.16 4.83 2.51 
∆ 0.02 0.00 0.11 
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NMR-spectroscopy:  
 
 
1H NMR (500 MHz, CDCl3): δ = 1.27 (t, 3J(H, H) = 8 Hz, 3H, H6'), 1.33 (d, 3J(H,H) 
= 7 Hz, 6H, Hf), 2.19 (s, 3H, H1''), 2.39 (s, 3H, Hg), 2.73–2.86 (m, 2H, He, H2'), 
2.90–2.96 (m, 1H, H2'), 4.16 (q, 3J(H,H) = 7 Hz, 2H, H5'), 4.21–4.33 (m, 2H, H1'), 
4.25–4.30 (m, 1H, H1'), 5.78 (t, 3J(H,H) = 5 Hz, 2H, Hb), 6.04 (d, 3J(H,H) = 5 Hz, 
2H, Hc), 6.17 (d, 3J(H,H) = 7 Hz, 1H, H5), 6.56 (d, 3J(H,H) = 7 Hz, 1H, H6) ppm.  
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3.5.19. [Chlorido(η5-pentamethylcyclopentadiene){N-   
  [(ehtylcarbonyl)ethyl)]-3-oxo-κO-4-methyl-2-(1H)-  
  pyridonato-κO}rhodium(III)] - 7d 
+
N O
OH
2 Rh Rh
Cl
Cl
Cl
Cl
N O
O
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MeOH
Rh
O O O O
Cl
2
 
Synthesis: 
The synthesis was performed according to the general procedure using 100 mg 
(0.16 mmol) of rhodium precursor p3, 77 mg (0.34 mmol) of compound 7a and 
22 mg (0.37 mmol) of NaOMe. The resolved crude product was precipitated by 
addition of n-hexane (20 mL). 
 
Yield: 100 mg (63%) 
 
Melting point: >170 °C (decomposition) 
 
Water solubility: 7.14 mg/mL 
 
Elemental analysis: calculated for C21H29ClNO4Rh·0.5H2O 
 
1c C[%] H[%] N[%] 
calculated 49.77 5.97 2.76 
found 49.63 5.82 2.79 
∆ 0.14 0.16 0.03 
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NMR-spectroscopy:  
 
 
1H NMR (500 MHz, CDCl3): δ = 1.27 (t, 3J(H,H) = 7 Hz, 3H, H6'), 1.74 (s, 15H, 
Hb), 2.18 (s, 3H, H1''), 2.77–2.85 (m, 1H, H2'), 2.93–2.99 (m, 1H, H2'), 4.08–4.18 
(m, 3H, H5', H1'), 4.37–4.41 (m, 1H, H1'), 6.14 (d, 3J(H,H) = 7 Hz, 1H, H5), 6.46 
(d, 3J(H,H) = 7 Hz, 1H, H6) ppm. 
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3.5.20. Bis[([(η6-p-cymene){N-(Carboxyl-ethyl)-3-oxo-κO-4-  
  methyl-2-(1H)-pyridonato-κO}ruthenium(II)] - 8b 
 
 
Synthesis: 
The synthesis was performed according to the general procedure using 100 mg 
(0.16 mmol) of ruthenium precursor p1, 71 mg (0.36 mmol) of compound 8a and 
42 mg (0.73 mmol) of NaOMe. No product was formed upon precipitation by 
addition of Et2O nor by n-hexane.  
 
Yield: >5 mg, dark red crystals (crystallization experiment) 
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3.5.21. Bis[([(η5-pentamethylcyclopentadiene){N-   
  [(ethoxycarbonyl)ethyl]-3-oxo-κO-4-methyl-2-(1H)-  
  pyridonato-κO}rhodium(III)] - 8d 
 
 
 
Synthesis: 
The synthesis was performed according to the general procedure using 100 mg 
(0.16 mmol) of ruthenium precursor p3, 67 mg (0.34 mmol) of compound 8a and 
41 mg (0.72 mmol) of NaOMe. The resolved crude product was precipitated by 
addition of n-hexane (20 mL). 
 
Yield: 78 mg (56%) 
 
Melting point: >164 °C (decomposition) 
 
Water solubility: 5.00 mg/mL 
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Mass spectrometry: m/z =  434 (C19H24NO4Rh) 
    456 (C18H22NO4Rh + Na+) 
    
867 (C36H44N2O8Rh2) 
    889 (C36H44N2O8Rh2 + Na+) 
 
NMR-spectroscopy:  
 
 
 
1H NMR (500 MHz, d4-CD3OD): δ = 1.74 (s, 15H, Hb), 2.17 (s, 3H, H1''), 2.70 (t, 
3J(H,H) = 7 Hz, 2H, H2'), 4.31 (t, 2H, H1'), 6.29 (d, 3J(H,H) = 7 Hz, 1H, H5), 6.87 
(d, 3J(H,H) = 7 Hz, 1H, H6) ppm. 
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4. Conclusion and Outlook 
 
Beside established platinum based drugs for chemotherapy, other metal 
complexes became potential candidates for cancer treatment such as the 
ruthenium(III)-based compounds KP1019 and NAMI-A. In this master thesis 
several “piano-stool” configured mono and dimerc ruthenium, osmium and 
rhodium complexes bearing 3-hydroxy-2-pyridones were synthesized and 
characterized. The chelating ligand system was modified through N-alkylation, 
Mannich reaction, followed by hydrogenation and hydrolysis of the ester moiety. 
X-ray diffraction analysis showed the formation of two possible intercalation sites 
for the C1 spacer complexes via π-stacking or interaction with the oxygens inside 
the cavity. With the used experimental setups no intercalation of alkali metals 
was observed. In water ruthenium and rhodium complexes showed good to 
excellent solubility, the osmium analogues only moderate or in some cases low 
solubility. Water stability tests revealed the immediately monomerization of the 
dimeric compounds to their charged aqua species, which was proven by variation 
of pH during pKa determination. Coordination to the DNA model compound 5'-
GMP via N7 of the purine ring was demonstrated for selected ruthenium and 
osmium compounds, while rhodium showed no interaction with the nucleobase.  
 
The in vitro activity of the dimeric complexes and the monomeric rhodium 
compounds should be investigated to compare the cytotoxicity between 
monomeric and dimeric compounds and between the transition metals for this 
ligand system. By switching to thionated pyridones the complex stability and the 
in vitro activity could be increased as it was reported for the (thio)maltolato-
ruthenium(II) arene complexes.26 Exchanging the carboxyl moiety e.g. by an 
amine group could be an opportunity to stabilize the dimeric structure. 
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